US20120115849A1 - Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors - Google Patents

Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors Download PDF

Info

Publication number
US20120115849A1
US20120115849A1 US13/290,868 US201113290868A US2012115849A1 US 20120115849 A1 US20120115849 A1 US 20120115849A1 US 201113290868 A US201113290868 A US 201113290868A US 2012115849 A1 US2012115849 A1 US 2012115849A1
Authority
US
United States
Prior art keywords
formula
alkyl
pde7
group
addictive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/290,868
Other languages
English (en)
Inventor
Gregory A. Demopulos
George A. Gaitanaris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Priority to US13/290,868 priority Critical patent/US20120115849A1/en
Assigned to OMEROS CORPORATION reassignment OMEROS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GAITANARIS, GEORGE A., DEMOPULOS, GREGORY A.
Publication of US20120115849A1 publication Critical patent/US20120115849A1/en
Priority to US13/835,607 priority patent/US9220715B2/en
Priority to US14/960,750 priority patent/US20160158247A1/en
Assigned to CRG SERVICING LLC, AS ADMINISTRATIVE AGENT reassignment CRG SERVICING LLC, AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OMEROS CORPORATION
Priority to US15/871,768 priority patent/US11207275B2/en
Priority to US16/191,119 priority patent/US11464785B2/en
Assigned to OMEROS CORPORATION reassignment OMEROS CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CRG SERVICING LLC
Priority to US17/530,011 priority patent/US20220062194A1/en
Priority to US17/823,793 priority patent/US20230110784A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • PDE7 phosphodiesterase 7
  • the World Health Organization defines substance addiction as using a substance repeatedly, despite knowing and experiencing harmful effects.
  • Substance addiction is a chronic, relapsing disease characterized by a loss of control over drug use, compulsive drug seeking and craving for a substance, use that persists despite negative consequences, and physical and/or psychological dependence on the substance.
  • Substance addiction typically follows a course of tolerance, withdrawal, compulsive drug taking behavior, drug seeking behavior, practice of addictive behavior, and relapse.
  • Substance abuse and addiction are public health issues with significant social and economic impact on both the addict and society by playing a major role in violent crime and the spread of infectious diseases.
  • Addictive substances include alcohol, caffeine, nicotine, cannabis (marijuana) and cannabis derivatives, opiates and other morphine-like opioid agonists such as heroin, phencyclidine and phencyclidine-like compounds, sedative hypnotics such as benzodiazepines and barbiturates and psychostimulants such as cocaine, amphetamines and amphetamine-related drugs such as dextroamphetamine and methylamphetamine.
  • Alcohol is one of the most commonly abused substances at a global level. Additionally, alcoholism leads to serious liver and cardiovascular disease and generates dependence resulting in severe mental disorders, social problems and adverse consequences including the division of families, tragic accidents and the reduction of work performance. According to the WHO, alcohol consumption is responsible for 20-30% of oesophageal and liver cancer, liver cirrhosis, homicides, epilepsy, and motor vehicle accidents worldwide. Globally, alcohol abuse leads to about 1.8 million deaths per year. Compulsive behavior towards the consumption of alcohol is a core symptom of the disorder.
  • Medications such as naltrexone, acamprosate, ondansetron, disulfiram, gamma hydroxybutyrate (GHB), and topiramate tested for their potential therapeutic effect on alcohol abuse belong to several classes (Volpicelli et al. 1992; O'Brien et al. 1997). Few of these pharmacotherapeutics, such as naltrexone, acamprosate, and disulfiram, have been proven to be of a certain utility and approved for the treatment of alcoholism. Among these medications, the non-selective opioid antagonist naltrexone is currently considered the pharmacological best option. However, despite some promising results none of these medications, including naltrexone, is of sufficient efficacy in alcoholism and prognosis remains poor.
  • Nicotine is one of the most widely used addictive drugs, and nicotine abuse is the most common form of substance abuse.
  • the WHO estimates that there are 1.25 billion smokers worldwide, representing one third of the global population over the age of 15. The WHO further estimates that 5 million deaths occur each year as a direct result of tobacco use, making nicotine abuse the largest single preventable cause of death worldwide.
  • 70-90% of lung cancer, 56-80% of chronic respiratory disease, and 22% of cardiovascular disease instances are attributed to nicotine addiction.
  • Cigarette smoking is associated with 430,000 deaths per year in the US alone and is estimated to cost the nation 80 billion dollars yearly in health care costs.
  • Tobacco use accounts for one third of all cancers, including cancer of the lung, mouth, pharynx, larynx, esophagus, cervix, kidney, ureter, and bladder.
  • the overall rates of death from cancer are twice as high among smokers as among nonsmokers.
  • Smoking also causes lung diseases such as chronic bronchitis and emphysema; exacerbates asthma symptoms; and increases the risk of heart disease, including stroke, heart attack, vascular disease, and aneurysm.
  • An estimated 20% of the deaths from heart disease are attributable to smoking.
  • Expectant women who smoke are at greater risk than nonsmokers for premature delivery, spontaneous abortion, and infants with decreased birth weight.
  • Nicotine use results in increased levels of the neurotransmitter dopamine, which activates the reward pathways to regulate feelings of pleasure and to mediate the desire to consume nicotine.
  • Symptoms associated with nicotine withdrawal include craving, irritability, anger, hostility, aggression, fatigue, depression, and cognitive impairment, which lead the abuser to seek more nicotine.
  • Environmental conditioning factors and exposure to psychological stress represent additional factors motivating nicotine use in smokers. Repeated nicotine use results in the development of tolerance, requiring higher doses of nicotine to produce the same initial stimulation.
  • Treatments include the use of nicotine replacement products, anti-depressants, anti-hypersensitives, and behavioral therapy.
  • the goals for treatment of opiate addiction are to discontinue the use of the opioid while minimizing painful withdrawal symptoms and preventing relapse.
  • Current treatments involve replacing the addictive drug with a substitution of an opioid receptor agonist or mixed agonist/antagonist.
  • An alternative approach consists of the use of an opioid receptor antagonist to block the effect of the agonist.
  • Antagonists provide no relief from pain or other withdrawal symptoms; rather, they can precipitate withdrawal, and their therapeutic use was associated with increased accidental opioid agonists overdosing and increased lethality.
  • Use of agonists with a lower affinity for the receptors results in the least severe withdrawal symptoms, but it can lead to a dependence on the substitute opiate.
  • substitution therapies take 3-6 months, allowing time for addicts to stop treatment midway.
  • Psychostimulants such as cocaine and amphetamines, temporarily cause euphoria, increased alertness, and increased physical capacity in humans. These substances first increase dopamine transmission, but long term drug usage results in a reduction of dopamine activity, leading to dysregulation of the brain reward system and dysphoria.
  • Chronic cocaine abuse can result in hyperstimulation, tachycardia, hypertension, mydriasis, muscle twitching, sleeplessness, extreme nervousness, hallucinations, paranoia, aggressive behavior, and depression.
  • Cocaine overdose may lead to tremors, convulsions, delirium, and death resulting from heart arrhythmias and cardiovascular failure.
  • Desipramine, amantadine and bromocriptine have been shown to decrease cocaine withdrawal symptoms.
  • Amphetamine withdrawal symptoms include EEG changes, fatigue, and mental depression. Tolerance develops over time and may be associated with tachycardia, auditory and visual hallucinations, delusions, anxiety reactions, paranoid psychosis, exhaustion, confusion, memory loss, and prolonged depression with suicidal tendencies.
  • Current treatments for amphetamine addiction include phenothiazines, haloperidol, and chlorpromazine for hallucinations, but potential side effects of these drugs include postural hypotension and severe extrapyramidal motor disorders. Subjects who are addicted to psychostimulants will sometimes go through psychological withdrawal as well as physiological withdrawal, making relapse potentially more likely.
  • Homeostatic hypotheses relate relapse risk to neuroadaptive changes and disruption of neuroendocrine homeostasis that are thought to underlie anxiety, mood dysregulation and somatic symptoms that accompany acute withdrawal, and that can persist for considerable periods of time during what has been referred to as the “protracted withdrawal” phase.
  • This view therefore, implicates alleviation of discomfort and negative affect as a motivational basis for relapse.
  • Conditioning hypotheses are based on observations that relapse is often associated with exposure to drug-related environmental stimuli. This view holds that specific environmental stimuli that have become associated with the rewarding actions of a drug by means of classical conditioning can elicit subjective states that trigger resumption of drug use.
  • the homeostatic and conditioning hypotheses are not mutually exclusive. In fact, homeostatic and conditioning factors are likely to exert additive effects in that exposure to drug-related environmental stimuli may augment vulnerability to relapse conveyed by homeostatic disturbances.
  • the present invention meets these needs by providing methods and pharmaceutical combinations useful in treating and preventing addiction and recidivism.
  • the present invention provides a method of treating or preventing an addiction by determining that a subject has an addiction or is at risk of developing an addiction and then administering an inhibitor of a phosphodiesterase 7 (PDE7) effective to the subject for the treatment or prevention of the addiction.
  • PDE7 phosphodiesterase 7
  • the subject is addicted to an addictive agent.
  • addictive agents include alcohol, nicotine, marijuana, a marijuana derivatives, opioid agonists, benzodiazepines, barbiturates, and psychostimulants.
  • the addictive agent is alcohol.
  • the addictive agent is nicotine.
  • the addictive agent is an opioid, e.g., morphine, methadone, fentanyl, sufentanil, codeine, oxycodeine, and heroin.
  • the addictive agent is a psychostimulant, e.g., cocaine, amphetamine or an amphetamine derivative.
  • the addictive agent is cocaine.
  • the subject is addicted to an addictive or compulsive behavior or suffers from an impulse-control disorder.
  • the subject suffers from a primary impulse-control disorder, i.e., an impulse-control disorder in which the disorder is a primary disorder rather than a disorder that is either iatrogenic (secondary to medical treatment) or that is secondary to another primary disease or disorder.
  • Addictive or compulsive behaviors that are primary impulse-control disorders include the following: binge eating, pathological gambling, pathological use of electronic devices, pathological use of electronic video games, pathological use of electronic communication devices, pathological use of cellular telephones, addiction to pornography, sex addiction, compulsive spending, anorexia, bulimia, intermittent explosive disorder, kleptomania, pyromania, trichotillomania, compulsive over-exercising, and compulsive overworking.
  • the addictive or compulsive behavior is binge eating.
  • the addictive or compulsive disorder is an obsessive-compulsive disorder.
  • the PDE7 inhibitory agents for treatment of addiction are selected from the following disclosed herein: formula 1A, formula 1B, formula 29, formula 30, formula 31, formula 32, formula 33, formula 34, formula 35, formula 36, formula 37, formula 38, formula 39, formula 40, formula 41, formula 42, formula 43A, formula 43B, formula 44, formula 45, formula 46, formula 47, formula 48, formula 49, formula 50, formula 51, formula 52, formula 53, formula 54, formula 6A, formula 6B, formula 6C, formula 6D, formula 6E, formula 6F, formula 6G, formula 6H, formula 16A, compound 1, compound 2, compound 3, and compound 4.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE7A and/or PDE7B activity of less than about 1 ⁇ M. In one embodiment, the PDE7 inhibitory agent has an IC 50 for inhibiting PDE7A and/or PDE7B activity of less than about 100 nM. In another embodiment, the PDE7 inhibitory agent has an IC 50 for inhibiting PDE1B activity of greater than 5 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE10 activity of greater than 5 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity. In a further embodiment, the PDE7 inhibitory agent has an IC 50 for inhibiting PDE3 activity of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and/or the IC 50 for inhibiting PDE7B activity. In another embodiment, the PDE7 inhibitory agent has an IC 50 for inhibiting PDE3 and PDE4 activity of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE 4 and PDE 8 activity of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 agent has an IC 50 for inhibiting PDE1, PDE2, PDE3, PDE 4, PDE 8, PDE10, and PDE11 activity of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent is a selective PDE7 inhibitor for which the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity is less than one tenth the IC 50 that the agent has for inhibiting the activity of any other PDE enzyme from the PDE1-6 and PDE8-11 enzyme families.
  • the PDE7 inhibitory agent is a highly selective PDE7 inhibitor for which the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity is less than one fiftieth the IC 50 that the agent has for inhibiting the activity of any other PDE enzyme from the PDE1-6 and PDE8-11 enzyme families.
  • the PDE7 inhibitory agent has a molecular weight of less than about 450 g/mole.
  • the PDE7 inhibitory agent is able to cross the blood/brain barrier.
  • the present invention provides a method of treating or preventing an addiction by determining that a subject has an addiction or is at risk of developing an addiction and then administering a chemical compound that inhibits PDE7 activity.
  • the chemical compound has the following characteristics: (i) an IC 50 for inhibiting PDE7A and/or PDE7B activity of less than about 1 ⁇ M; and (ii) an IC 50 for inhibiting PDE 3 greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and/or the IC 50 for inhibiting PDE7B activity.
  • the chemical compound has an IC 50 for inhibiting PDE7A and/or PDE7B activity of less than about 100 nM.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE1B activity of greater than 5 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE10 activity of greater than 5 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE4 activity of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE8 activity of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 agent has an IC 50 for inhibiting PDE1, PDE2, PDE3, PDE 4, PDE 8, PDE10, and PDE11 activity of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent is a selective PDE7 inhibitor for which the lesser of the IC50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity is less than one tenth the IC 50 that the agent has for inhibiting the activity of any other PDE enzyme from the PDE1-6 and PDE8-11 enzyme families.
  • the PDE7 inhibitory agent is a highly selective PDE7 inhibitor for which the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity is less than one fiftieth the IC 50 that the agent has for inhibiting the activity of any other PDE enzyme from the PDE1-6 and PDE8-11 enzyme families.
  • the PDE7 inhibitory agent has a molecular weight of less than about 450 g/mole.
  • the PDE7 inhibitory agent is able to cross the blood/brain barrier.
  • the subject is addicted to an addictive agent.
  • addictive agents include alcohol, nicotine, marijuana, a marijuana derivatives, opioid agonists, benzodiazepines, barbiturates, and psychostimulants.
  • the addictive agent is alcohol.
  • the addictive agent is nicotine.
  • the addictive agent is an opioid, e.g., morphine, methadone, fentanyl, sufentanil and heroin.
  • the addictive agent is a psychostimulant, e.g., cocaine, amphetamine or an amphetamine derivative.
  • the addictive agent is cocaine.
  • the subject is addicted to an addictive or compulsive behavior or suffers from an impulse-control disorder.
  • the subject suffers from a primary impulse-control disorder, i.e., an impulse-control disorder in which the disorder is a primary disorder rather than a disorder that is either iatrogenic (secondary to medical treatment) or that is secondary to another primary disease or disorder.
  • Addictive or compulsive behaviors that are primary impulse-control disorders include the following: binge eating, pathological gambling, pathological use of electronic devices, pathological use of electronic video games, pathological use of electronic communication devices, pathological use of cellular telephones, addiction to pornography, sex addiction, compulsive spending, anorexia, bulimia, intermittent explosive disorder, kleptomania, pyromania, trichotillomania, compulsive over-exercising, and compulsive overworking.
  • the addictive or compulsive behavior is binge eating.
  • the subject to be treated in accordance with the present invention has an obsessive-compulsive disorder.
  • the present invention also provides a method of treating or preventing an addiction, comprising providing to a subject having an addiction, an inhibitor of a phosphodiesterase 7 (PDE7) and an additional therapeutic agent, wherein each of the PDE7 inhibitor and the additional therapeutic agent contribute to the effective treatment or prevention of the addiction.
  • Additional therapeutic agents include, e.g., opioid antagonists, mixed opioid partial agonist/antagonists, antidepressants, antiepileptics, antiemetics, corticotrophin-releasing factor-1 (CRF-1) receptor antagonists, selective serotonin-3 (5-HT3) antagonists, 5-HT2A/2C antagonists, and cannabinoid-1 (CB1) receptor antagonists.
  • Exemplary opioid antagonists include naltrexone and nalmefene.
  • Exemplary antidepressants include fluoxetine, mirtazapine, and bupropion.
  • Exemplary antiepileptics include topiramate, levetiracetam, and gabapentin.
  • Antalarmin is an exemplary CRF-1 receptor antagonist.
  • Ondensetrom is an exemplary selective serotonin-3 (5-HT3) antagonist.
  • Exemplary cannabinoid-1 (CB1) receptor antagonists are rimonabant and abant.
  • Buprenorphine is an exemplary mixed opioid agonist/antagonist.
  • Exemplary opioid agonists include morphine, methadone, fentanyl, sufentanil and heroin.
  • the subject is addicted to an addictive agent, e.g., alcohol, nicotine, marijuana, a marijuana derivative, an opioid agonist, a benzodiazepine, a barbiturate, and a psychostimulant.
  • the addictive agent is alcohol and the additional therapeutic agent is an opioid antagonist, such as naltrexone, or a mixed opioid antagonist/partial agonist, such as buprenorphine.
  • the subject is addicted to a psychostimulant such as cocaine, amphetamine, an amphetamine derivative, or methamphetamine and the additional therapeutic agent is an antidepressant, such as bupropion.
  • the subject is addicted nicotine and the additional therapeutic agent is an antidepressant, such as bupropion.
  • the subject is addicted to an addictive or compulsive behavior, such as a primary impulse-control disorder, including, for example, pathological gambling, binge eating, pathological use of electronic devices, pathological use of electronic video games, pathological use of electronic communication devices, pathological use of cellular telephones, addiction to pornography, sex addiction, compulsive spending, anorexia, bulimia, intermittent explosive disorder, kleptomania, pyromania, trichotillomania, compulsive over-exercising, and compulsive overworking.
  • the addictive or compulsive behavior is binge eating and the additional therapeutic agent is topiramate.
  • the subject to be treated in accordance with the present invention has an obsessive-compulsive disorder.
  • the present invention provides a method of preventing relapse use of an addictive agent or practice of an addictive or compulsive behavior, by treating a subject who has undergone a period of abstinence from, or limited or reduced use of, the addictive agent or the addictive or compulsive behavior by administering a PDE7 inhibitor to the subject.
  • the present invention also provides a method of preventing relapse of an addictive or compulsive behavior associated with a primary impulse-control disorder, by treating a subject who has undergone a period of remission from, or limited or reduced practice of, the addictive or compulsive behavior associated with the primary impulse-control disorder by administering a PDE7 inhibitor to the subject.
  • the present invention also provides a method of preventing relapse of addictive or compulsive behavior associated with an obsessive-compulsive disorder, by treating a subject who has undergone a period of remission from, or limited or reduced practice of, the addictive or compulsive behavior associated with the obsessive-compulsive disorder by administering a PDE7 inhibitor to the subject. Additional therapeutic agents that contribute to the effect prevention of relapse can be administered with the PDE7 inhibitor. This treatment can be administered to subjects that have previously been treated with a different anti-addiction treatment that is no longer being used.
  • the relapse use of addictive agents such as alcohol, nicotine, marijuana, marijuana derivatives, opioid agonists, benzodiazepines, barbiturates, and psychostimulants is prevented through the administration of PDE7 inhibitors.
  • addictive agents such as alcohol, nicotine, marijuana, marijuana derivatives, opioid agonists, benzodiazepines, barbiturates, and psychostimulants
  • PDE7 inhibitors In a preferred embodiment, the relapse use of cocaine, amphetamine, or methamphetamine is prevented.
  • the relapse of an addictive or compulsive behavior is prevented through the administration of PDE7 inhibitors.
  • the relapse of the following behaviors is prevented: binge eating, pathological gambling, pathological use of electronic devices, pathological use of electronic video games, pathological use of electronic communication devices, pathological use of cellular telephones, addiction to pornography, sex addiction, compulsive spending, anorexia, bulimia, intermittent explosive disorder, kleptomania, pyromania, trichotillomania, compulsive over-exercising, and compulsive overworking.
  • the addictive or compulsive behavior is binge eating that has been induced by stress.
  • the subject is treated to prevent relapse of addictive or compulsive behavior associated with an obsessive-compulsive disorder.
  • the present invention provides a pharmaceutical composition that includes a PDE7 inhibitor and an additional therapeutic agent, where both the PDE7 inhibitor and the additional therapeutic agent contribute to the effective treatment or prevention of an addiction.
  • Unit dosages of the pharmaceutical composition are also provided.
  • the subject is addicted to an addictive agent.
  • addictive agents include alcohol, nicotine, marijuana, marijuana derivatives, opioid agonists, benzodiazepines, barbiturates, cocaine and other psychostimulants.
  • the addictive agent is alcohol.
  • the addictive agent is nicotine.
  • the addictive agent is an opioid, e.g., morphine, methadone, fentanyl, sufentanil and heroin.
  • the addictive agent is a psychostimulant, e.g., cocaine, amphetamine or an amphetamine derivative.
  • the addictive agent is cocaine.
  • the subject is addicted to an addictive or compulsive behavior or suffers from an impulse-control disorder.
  • the subject suffers from a primary impulse-control disorder, i.e., an impulse-control disorder in which the disorder is a primary disorder rather than a disorder that is either iatrogenic (secondary to medical treatment) or that is secondary to another primary disease or disorder.
  • Addictive or compulsive behaviors that are primary impulse-control disorders include the following: binge eating, pathological gambling, pathological use of electronic devices, pathological use of electronic video games, pathological use of electronic communication devices, pathological use of cellular telephones, addiction to pornography, sex addiction, compulsive spending, anorexia, bulimia, intermittent explosive disorder, kleptomania, pyromania, trichotillomania, compulsive over-exercising, and compulsive over-working.
  • the addictive or compulsive behavior is binge eating.
  • the subject to be treated in accordance with the present invention has an obsessive-compulsive disorder.
  • the additional therapeutic agent of the pharmaceutical composition is an opioid antagonist, a mixed opioid partial agonist/antagonist, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist, or a cannabinoid-1 (CB1) receptor antagonist.
  • Exemplary opioid antagonists include naltrexone or nalmefene.
  • Exemplary antidepressants include fluoxetine, mirtazapine, or bupropion.
  • Exemplary antiepileptics include topiramate, levetiracetam, and gabapentin.
  • Antalarmin is an exemplary CRF-1 receptor antagonist.
  • Ondensetrom is an exemplary selective serotonin-3 (5-HT3) antagonist.
  • Exemplary cannabinoid-1 (CB1) receptor antagonists are rimonabant and abant.
  • Buprenorphine is an exemplary mixed opioid agonist/antagonist.
  • the subject is addicted to an addictive agent, e.g., alcohol, nicotine, marijuana, a marijuana derivative, an opioid agonist, a benzodiazepine, a barbiturate, and a psychostimulant.
  • the addictive agent is alcohol and the additional therapeutic agent is an opioid antagonist, such as naltrexone, or a mixed opioid antagonist/partial agonist, such as buprenorphine.
  • the addictive agent is nicotine and the additional therapeutic agent is varenicline.
  • the subject is addicted to a psychostimulant such as cocaine, amphetamine, an amphetamine derivative, or methamphetamine and the additional therapeutic agent is an antidepressant, such as bupropion.
  • the subject is addicted nicotine and the additional therapeutic agent is an antidepressant, such as bupropion.
  • the subject is addicted to more than one addictive agents and the additional therapeutic agent is an opioid antagonist, such as naltrexone, or a mixed opioid antagonist/partial agonist, such as buprenorphine.
  • the present invention provides a kit for the treatment or prevention of an addiction.
  • the kit includes a first container containing a PDE7 inhibitor and a second container containing an additional therapeutic agent. Both the PDE7 inhibitor and the additional therapeutic agent contribute to the effective treatment or prevention of an addiction.
  • the additional therapeutic agent of the pharmaceutical composition is an opioid antagonist, a mixed opioid partial agonist/antagonist, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist, or a cannabinoid-1 (CB1) receptor antagonist.
  • Exemplary opioid antagonists include naltrexone and nalmefene.
  • Exemplary antidepressants include fluoxetine, mirtazapine, and bupropion.
  • Exemplary antiepileptics include topiramate, levetiracetam, and gabapentin.
  • Antalarmin is an exemplary CRF-1 receptor antagonist.
  • Ondensetrom is an exemplary selective serotonin-3 (5-HT3) antagonist.
  • Exemplary cannabinoid-1 (CB1) receptor antagonists are rimonabant and abant.
  • Buprenorphine is an exemplary mixed opioid agonist/antagonist.
  • the subject is addicted to an addictive agent, e.g., alcohol, nicotine, marijuana, a marijuana derivative, an opioid agonist, a benzodiazepine, a barbiturate, and a psychostimulant.
  • the addictive agent is alcohol and the additional therapeutic agent is an opioid antagonist, such as naltrexone, or a mixed opioid antagonist/partial agonist, such as buprenorphine.
  • the subject is addicted to a psychostimulant such as cocaine, amphetamine, an amphetamine derivative, or methamphetamine and the additional therapeutic agent is an antidepressant, such as bupropion.
  • the subject is addicted nicotine and the additional therapeutic agent is an antidepressant, such as bupropion.
  • the subject is addicted to more than one addictive agents and the additional therapeutic agent is an opioid antagonist, such as naltrexone, or a mixed opioid antagonist/partial agonist, such as buprenorphine.
  • a subject at risk of addiction to an addictive substance is administered the addictive substance in combination with a PDE7 inhibitor.
  • a subject that will be administered an opioid agonist for the relief of acute or chronic pain is administered an opioid agonist in combination with a PDE7 inhibitor such that non-addictive or less addictive analgesia is provided.
  • Examples of addictive agents that may be administered in combination with a PDE7 inhibitor, as either a fixed-dose combination or as a kit, include benzodiazepines, barbiturates, and pain medications including alfentanil, allylprodine, alphaprodine, anileridine benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypeth
  • PDE7 inhibitors are used formula 1A, formula 1B, formula 29, formula 30, formula 31, formula 32, formula 33, formula 34, formula 35, formula 36, formula 37, formula 38, formula 39, formula 40, formula 41, formula 42, formula 43A, formula 43B, formula 44, formula 45, formula 46, formula 47, formula 48, formula 49, formula 50, formula 51, formula 52, formula 53, formula 54, formula 6A, formula 6B, formula 6C, formula 6D, formula 6E, formula 6F, formula 6G, formula 6H, formula 16A, compound 1, compound 2, compound 3, and compound 4.
  • FIG. 1 demonstrates the effect of OMS182056, a PDE7 inhibitor, on cocaine self-administration by rats.
  • FIG. 2 demonstrates the effect of OMS181869, a PDE7 inhibitor, on cocaine self-administration by rats.
  • FIG. 3 demonstrates the effect of SKF82958, a dopamine D1 agonist, on cocaine self-administration by rats.
  • FIG. 4 demonstrates the effect of OMS182056, a PDE7 inhibitor, on cocaine priming-induced relapse by rats.
  • FIG. 5 demonstrates the effect of SKF82958, a dopamine D1 agonist, on cocaine priming-induced relapse by rats.
  • FIG. 6 demonstrates the effect of OMS182056, a PDE7 inhibitor, on non-reinforced lever-press response by rats.
  • FIG. 7 demonstrates the effect of SKF82958, a dopamine D1 agonist, on non-reinforced lever-press response by rats.
  • FIG. 8 demonstrates the effect of OMS182056, a PDE7 inhibitor, on lever-press response by rats on the first day of extinction following cocaine addiction.
  • FIG. 9 demonstrates the effect of OMS182056, a PDE7 inhibitor, on yohimbine-induced relapse by rats.
  • FIG. 10 demonstrates the effect of OMS182401, a PDE7 inhibitor, on yohimbine-induced relapse by rats.
  • FIG. 11 demonstrates the effect of OMS182056, a PDE7 inhibitor, on cue-induced relapse by rats.
  • FIGS. 12A-12D demonstrates the effect of OMS182401, a PDE7 inhibitor, on stress induce binge eating by rats.
  • FIG. 12A shows the results for control animals, which were not stressed or subjected to dietary restriction.
  • FIG. 12B shows the results for experimental animals that were not stressed and were subjected to dietary restriction.
  • FIG. 12C shows the results for experimental animals that were stressed and were not subjected to dietary restriction.
  • FIG. 12D shows the results for experimental animals that were stressed and were subjected to dietary restriction.
  • FIG. 13 demonstrates the effect of OMS182401, a PDE7 inhibitor, on cue-induced relapse by rats.
  • FIG. 14 demonstrates the chronic effect of OMS182401, a PDE7 inhibitor, on cocaine self-administration in rats.
  • FIG. 15 demonstrates the effect of OMS182401, a PDE7 inhibitor, on nicotine self-administration in rats using a short access model.
  • FIG. 16 demonstrates the effect of OMS182401, a PDE7 inhibitor, on nicotine self-administration in rats using a long access model.
  • FIG. 17 demonstrates the effect of OMS182401, a PDE7 inhibitor, on the first day of extinction of nicotine self-administration.
  • FIG. 18 demonstrates the effect of OMS182401, a PDE7 inhibitor, on cue-induced reinstatement of nicotine seeking behavior.
  • FIG. 19 demonstrates the effect of OMS182401, a PDE7 inhibitor, on yohimbine-induced reinstatement of nicotine seeking behavior.
  • FIG. 20 demonstrates the effect of OMS182399, a PDE7 inhibitor, on nicotine self-administration in rats using a short access model.
  • the present invention is based upon the surprising discovery by the present inventors that selective inhibitors of the type 7 cyclic nucleotide phosphodiesterase (PDE7) cause a striking decrease in relapse of addiction. Using rat models, the decreases were demonstrated in subjects addicted to addictive agents and in subjects that exhibited compulsive behaviors.
  • PDE7 cyclic nucleotide phosphodiesterase
  • the present invention includes methods of treating or preventing an addiction, comprising administering one or more PDE7 inhibitors to a subject having an addiction or at risk for developing an addiction.
  • the subject is addicted to an addictive agent or behavior, including, but not limited to, any of the addictive agents and behaviors described herein.
  • the subject may be physically or physiologically dependent on the substance or behavior; the subject may be psychologically dependent; or the subject may be both physically and psychologically dependent.
  • the subject may be addicted to one or more than one addictive agent or behavior.
  • treat is an approach for obtaining beneficial or desired results, including and preferably clinical results.
  • Treatment can involve optionally either the reducing or amelioration of a disease or condition, (e.g., addiction or relapse use or behavior), or the delaying of the progression of the disease or condition (e.g., addiction, or relapse use or behavior).
  • a disease or condition e.g., addiction or relapse use or behavior
  • the delaying of the progression of the disease or condition e.g., addiction, or relapse use or behavior.
  • prevention is an approach for preventing the onset or recurrence of a disease or condition, (e.g., addiction, or relapse use or behavior) or preventing the occurrence or recurrence of the symptoms of a disease or condition, or optionally an approach for delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease or condition.
  • prevention is an approach for preventing the onset or recurrence of a disease or condition, (e.g., addiction, or relapse use or behavior) or preventing the occurrence or recurrence of the symptoms of a disease or condition, or optionally an approach for delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease or condition.
  • PDE7 is used generically to refer to all translation products coded by transcripts of either or both of these two genes: PDE7A and/or PDE7B.
  • PDE7 inhibitory agent or “inhibitor of PDE7” refers to an agent, such as a chemical compound, a peptide, or a nucleic acid molecule, that directly or indirectly inhibits or blocks the phosphodiesterase activity of PDE7A, PDE7B, or PDE7A and PDE7B.
  • the agent may bind or interact directly with PDE7 protein.
  • An agent that binds to PDE7 may act to inhibit or block the PDE7 activation by any suitable means, such as by inhibiting the binding of cAMP or substrate ligand with PDE7.
  • the PDE7 inhibitory agent may inhibit PDE7 activity indirectly, such as by decreasing expression of the PDE7 protein.
  • the PDE7 inhibitory agent may inhibit PDE7 activity by altering the cellular distribution of PDE7, for example, by interfering with the association between PDE7 and an intracellular anchoring protein.
  • mammalian subject includes all mammals, including without limitation humans, non-human primates, dogs, cats, horses, sheep, goats, cows, rabbits, pigs, and rodents.
  • an “effective amount” or a “therapeutically effective amount” of a substance is that amount sufficient to affect a desired biological or psychological effect, such as beneficial results, including clinical results.
  • an effective amount of a PDE7 inhibitor is that amount sufficient to cause the subject to reduce or discontinue use of an addictive agent.
  • an effective amount of a PDE7 inhibitor is that amount sufficient to cause the subject to reduce or discontinue the addictive behavior.
  • a therapeutically effective dose is an amount of PDE7 inhibitory agent sufficient to inhibit PDE7 enzyme activity in a neuronal cell. In another embodiment of the methods of the invention, a therapeutically effective dose is an amount of PDE7 inhibitory agent sufficient to inhibit PDE7 enzyme activity in striatal neurons or nucleus acumbens.
  • the determination of an effective dose of a PDE7 inhibitory agent sufficient to cross a cellular membrane and inhibit PDE7 enzyme activity within a cell may be determined using a cellular assay for PDE7 inhibition, such as described by Smith S. J. et al., Molecular Pharmacology 66(6): 1679-1689 (2004), hereby incorporated by reference.
  • the determination of an effective dose of a PDE7 inhibitory agent sufficient to inhibit PDE7 enzyme activity in the striatum may be determined using an assay for measuring the effect of a PDE inhibitory agent on cAMP levels in the striatum, as described in Siuciak J. A. et al., Neuropharmacology 51: 386-396 (2006), hereby incorporated by reference.
  • a subject is provided with a PDE7 inhibitor alone, while in other embodiments, a subject is provided with a PDE7 inhibitor in combination with an additional therapeutic agent.
  • the effective amount of either or both of a PDE7 inhibitor and an additional therapeutic agent may be different when either is provided alone than when provided in combination.
  • a lower amount of the PDE7 inhibitor, a lower amount of the additional therapeutic agent, or lower amounts of both the PDE7 inhibitor or the additional therapeutic agent may be required to achieve the same therapeutic effect that would be provided by either the PDE7 inhibitor or the additional therapeutic agent alone.
  • the same amount of the PDE7 inhibitor and the additional therapeutic agent are used to provide an enhanced therapeutic effect relative to the therapeutic effect provided by either the PDE7 inhibitor or the additional therapeutic agent alone.
  • a subject is provided with a PDE7 inhibitor in combination with an addictive therapeutic agent, with the dosage of the addictive therapeutic agent being determined to achieve the desired therapeutic effect and the dosage of the PDE7 inhibitor being determined to eliminate or reduce the potential for addiction to the addictive therapeutic agent.
  • the subject may be any animal, including a mammal, and, particularly, a human.
  • the subject is first determined or diagnosed to have an addiction, or to be at risk of developing an addiction, by diagnostic testing, observation or analysis by a medical care provider.
  • An effective amount of a PDE7 inhibitor, or an effective amount of a PDE7 inhibitor and one additional therapeutic agent, are then provided to the subject for treatment or prevention of the addiction.
  • the subject is first determined or diagnosed to have an addiction, or to be at risk of developing an addiction, by diagnostic testing, observation or analysis by a medical care provider, but the subject has not been diagnosed or determined to have diabetes or other insulin disorder.
  • An effective amount of a PDE7 inhibitor, or an effective amount of a PDE7 inhibitor and one additional therapeutic agent are then provided to the subject for treatment or prevention of the addiction.
  • the dosage of the PDE7 inhibitor, or the PDE7 inhibitor and the one additional therapeutic agent may be specifically determined by the medical practitioner for treatment or prevention of the addiction rather than for any other disorder or disease.
  • the subject is suffering from or at risk for addiction to any physically addictive agent or addictive or compulsive behavior, including, e.g., any of those described below.
  • the subject is addicted to alcohol, cocaine, nicotine, marijuana, an opiate or other opioid agonist or methamphetamine or other psychostimulant, or phencyclidine and phencyclidine derivatives.
  • the subject suffers from a primary impulse-control disorder.
  • the subject suffers from obsessive-compulsive disorder.
  • the subject has a history of repeated dieting and is at risk of binge eating.
  • a subject is considered at risk of addiction or relapse to use of an addictive agent or practice of an addictive behavior when the subject has previously been addicted to the same or a different addictive agent or addictive or compulsive behavior.
  • the subject is considered at risk of addiction or relapse to use of an addictive agent or practice of an addictive behavior when the subject is psychologically addicted to an addictive agent or addictive or compulsive behavior, even if the subject is no longer physically addicted.
  • the addictive behavior is binge eating.
  • Subjects at risk of binge eating typically have at least one of the following in their history: recurring food restrictions or yo-yo dieting, eating in response to environmental stress, preference for highly palatable and high caloric food, eating after reaching fullness, and eating to the point of discomfort.
  • the subject suffers from a primary impulse-control disorder.
  • the subject is addicted to or at risk of becoming addicted to a therapeutic agent provided to the patient to treat a disease or disorder, e.g., a pain medication.
  • the subject may be at risk of abusing an addictive therapeutic agent, such as a pain medication.
  • Abusing an addictive therapeutic agent in certain embodiments, is understood to indicate using the agent for a reason different than or in addition to its prescribed use.
  • a subject may be provided with both an addictive therapeutic agent and a PDE7 inhibitor, alone or in combination with an additional therapeutic agent.
  • a subject suffering from pain, or at risk of pain may be provided with an opioid agonist and a PDE7 inhibitor, to both provide analgesia and prevent or treat addiction to the opioid agonist.
  • the subject is provided with the PDE7 inhibitor at the same time that the subject is using an addictive agent, after the subject has discontinued use of an addictive agent, or before the subject begins using an addictive agent.
  • addiction is used to describe a recurring compulsion by an individual to engage in some specific activity, despite harmful consequences to the individual's health, mental state or social life.
  • the term is often reserved for drug addictions, but it is applied to other compulsions, such as problem gambling, and binge eating.
  • Factors that have been suggested as causes of addiction include genetic, biological/pharmacological and social factors.
  • Addiction is now narrowly defined as “uncontrolled, compulsive use.” If there is no harm being suffered by, or damage done to, the patient or another party, then clinically it may be considered compulsive, but to the definition of some it is not categorized as “addiction”. In practice, the two kinds of addiction (physiological dependence and psychological dependence) are not always easy to distinguish. Addictions often have both physical and psychological components.
  • “Physical dependence” refers to a state resulting from habitual use of a drug, where negative physical withdrawal symptoms result from abrupt discontinuation.
  • addictive agents for which a user may develop a physical dependence include nicotine, opioids, barbiturates, benzodiazepines, alcohol, i.e., ethyl alcohol, GHB, and methaqualone.
  • addictive agent(s) includes any and all agents to which a subject can become addicted, either physically or psychologically, or both.
  • addiction includes addiction to chemical entities, such as drugs, e.g., ethyl alcohol, nicotine, or cocaine, as well as addiction to other behaviors, e.g., binge eating disorder, pathological gambling, pathological use of electronic devices, e.g., BlackBerry®, pathological use of electronic video games, pathological use of electronic communication devices, pathological use of cellular telephones, addiction to pornography, sex addiction, obsessive-compulsive disorder, compulsive spending, intermittent explosive disorder, kleptomania, pyromania, trichotillomania, compulsive over-exercising, and compulsive overworking.
  • Binge eating disorder or “binge eating” includes at least one of the following symptoms: eating large amounts of food, eating even when full, rapid eating, feeling that eating behavior is out of control, eating substantial amounts of food when not hungry, frequent dieting possibly without weight loss, eating alone, feeling depressed or disgusted about eating habits, eating in response to stress. Binge eating disorder is distinct from bulimia and binge purge syndromes.
  • Addictive agents include addictive recreational drugs, as well as addictive medications.
  • addictive agents include, but are not limited to, alcohol, e.g., ethyl alcohol, gamma hydroxybutyrate (GHB), caffeine, nicotine, cannabis (marijuana) and cannabis derivatives, opiates and other morphine-like opioid agonists such as heroin, phencyclidine and phencyclidine-like compounds, sedative hypnotics such as benzodiazepines, methaqualone, mecloqualone, etaqualone and barbiturates and psychostimulants such as cocaine, amphetamines and amphetamine-related drugs such as dextroamphetamine and methylamphetamine.
  • alcohol e.g., ethyl alcohol, gamma hydroxybutyrate (GHB), caffeine, nicotine, cannabis (marijuana) and cannabis derivatives
  • opiates and other morphine-like opioid agonists such as heroin, phencyclidine and phencycl
  • Examples of addictive medications include, e.g., benzodiazepines, barbiturates, and pain medications including alfentanil, allylprodine, alphaprodine, anileridine benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorph
  • a subject may be addicted to an opioid agonist.
  • opioid agonist used interchangeably herein and are used to designate a group of drugs that are, to varying degrees, opium- or morphine-like in their properties. Their main use is for pain relief. These agents work by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. Opiates are also addictive agents.
  • Opiates include alfentanil, allylprodine, alphaprodine, anileridine, apomorphine, benzylmorphine, beta-hydroxy 3-methylfentanyl, bezitramide, carfentanil, clonitazene, codeine, desomorphine, dextromoramide, diacetylmorphine (heroin), diampromide, dihydrocodeine, dihydroetorphine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, fentanyl, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, LMM, levorphan
  • Naturally occurring opiates include codeine, morphine, noscapine, papaverine, and thebaine.
  • Semi-synthetic opioids include diacetylmorphine, hydrocodone, hydromorphone, levorphanol, metapon, nalorphine, naloxone, naltrexone, oxycodone, oxymorphone, and tramadol.
  • Synthetic opioids include ethoheptazine, fentanyl, levorphanol, meperidine, methadone, phenazocine, propoxyphene and sufentanil.
  • phenanthrenes include codeine, etorpine, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone.
  • phenylheptylamines include dimeheptanol, dimenoxadol, dipipanone, isomethadone, methadone, methadyl acetate, and propoxyphene.
  • phenylpiperidines include alfentanyl, alphaprodine, beta-promedol, carfentanyl, fentanyl, lofentanil, meperidine, properidine, and sufentanil.
  • psychostimulants include, by way of example, amphetamine, cocaine, dextroamphetamine, methamphetamine, pemoline, Ritalin, Adderall and methylenedioxymethamphetamine.
  • Addiction to two or more addictive agents or addictive behaviors is referred to as polyaddiction.
  • PDE7 inhibitors may be effectively used in combination with one or more additional therapeutic agents to treat or prevent addiction, including addiction to one or more of the addictive agents described herein and compulsive or addictive behavior.
  • the present invention includes methods of treating or preventing an addiction, comprising administering to a subject addicted to an addictive agent one or more PDE7 inhibitor(s) and one or more additional therapeutic agent(s), in which each of the PDE7 inhibitor(s) and the additional therapeutic agent(s) contribute to the effective treatment or prevention of the addiction.
  • a subject is provided with or administered one PDE7 inhibitor and one additional therapeutic agent.
  • a subject is addicted to two or more addictive agents.
  • the PDE7 inhibitor and the additional therapeutic agent may be administered at the same time (i.e., concurrently), or either may be administered before the other (i.e., sequentially).
  • both the PDE7 inhibitor and the additional therapeutic agent are present in the subject at the same time for a duration of time and at levels sufficient to provide a therapeutic benefit to the subject, i.e., in the treatment or preventing of an addiction or the prevention of a relapse use (or reinstatement) of an addictive agent or compulsive or addictive behavior.
  • the PDE7 inhibitor and the additional therapeutic agent may be administered by the same or different routes of administration.
  • the PDE7 inhibitor and the additional therapeutic agent are each provided to a subject according to a standard route of administration of a commercially available or other pharmaceutical composition.
  • the PDE7 inhibitor and the additional therapeutic agent are co-administered using a composition comprising both agents.
  • the additional therapeutic agent provided in combination with a PDE7 inhibitor may be any therapeutic agent that contributes to an aspect of the effective treatment or prevention of the addiction.
  • the additional therapeutic agent may be a drug used to treat an addiction or a drug used to alleviate side-effects associated with physiological withdrawal from an addictive agent.
  • the additional therapeutic agent may be any drug that affects brain serotonin neurotransmission, such as selective serotonin reuptake inhibitors (SSRIs), and tricyclic and tetracyclic serotonin and norepinephrine reuptake inhibitors (SNRIs) as described below, and serotonin agonists such as sumatriptan, ergonovine, dihydroergotamine and buspirone.
  • SSRIs selective serotonin reuptake inhibitors
  • SNRIs tricyclic and tetracyclic serotonin and norepinephrine reuptake inhibitors
  • the additional therapeutic agent is an opioid antagonist, including mixed opioid partial agonist/antagonists, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist such as mianserin, mirtazapine and ketanserin, or a cannabinoid-1 (CB1) receptor antagonist, including but not limited to those therapeutic agents specifically described herein.
  • an opioid antagonist including mixed opioid partial agonist/antagonists, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist such as mianserin, mirtazapine and ketanserin, or a cannabinoid-1 (CB1) receptor antagonist, including but not limited to those therapeutic agents specifically described herein.
  • the addictive agent is alcohol and the additional therapeutic agent is an opioid antagonist or a mixed opioid antagonist/partial agonist.
  • the opioid antagonist is naltrexone.
  • the mixed opioid partial agonist/antagonist is buprenorphine.
  • the addictive agent is alcohol
  • the additional therapeutic agent is topiramate or levetiracetam.
  • the addictive agent is nicotine and the additional therapeutic agent is an antidepressant.
  • the antidepressant is bupropion.
  • the addictive agent is cocaine
  • the additional therapeutic agent is buprenorphine
  • the addictive agent is a psychostimulant and the additional therapeutic agent is an antidepressant.
  • the antidepressant is bupropion.
  • the addictive behavior is binge eating and the additional therapeutic agent is an antidepressant or an antiepileptic.
  • the antidepressant is sibutramine.
  • the antidepressant is fluoxetine.
  • the antiepileptic is topiramate.
  • the addictive agent is nicotine
  • the additional therapeutic agent is an anti-epileptic.
  • the anti-epileptic is levetiracetam.
  • the anti-epileptic agent is naltrexone.
  • the subject is addicted to two or more addictive agents and the additional therapeutic agent is an opioid antagonist or a mixed opioid partial agonist/antagonist.
  • the mixed opioid partial agonist/antagonist is buprenorphine.
  • the subject is addicted to both alcohol and nicotine, and the additional therapeutic agent is an anti-epileptic.
  • the anti-epileptic is naltrexone.
  • combinations to be administered in accordance with the present invention include a PDE7 inhibitor and an opioid agonist or a mixed opioid antagonist/partial antagonist, a PDE7 inhibitor and an antidepressant, a PDE7 inhibitor and a CB1 receptor antagonist/inverse agonist, a PDE7 inhibitor and varenicline, a PDE7 inhibitor and acamprosate, and a PDE7 inhibitor and disulfuram.
  • combinations to be administered in accordance with the present invention include, e.g., a PDE7 inhibitor and an antidepressant or a PDE7 inhibitor and a partial opioid agonist/antagonist, e.g., buprenorphine.
  • combinations to be administered in accordance with the present invention include, e.g., a PDE7 inhibitor and an antidepressant, a PDE7 inhibitor and nicotine (as a replacement, in an oral, transcutaneous or other conventional formulation), a PDE7 inhibitor and an opioid antagonist, a PDE7 inhibitor and a CB1 receptor antagonist/inverse agonist, and a PDE7 inhibitor and varenicline.
  • an addictive agent such as nicotine, and a PDE7 inhibitor are administered together using a transdermal patch delivery system.
  • kits including multiple transdermal patches including dosages of nicotine in diminishing levels and dosages of a PDE7 inhibitor in either constant or diminishing levels, are provided for sequential use by a subject addicted to nicotine to wean the subject from nicotine addiction.
  • combinations to be administered in accordance with the present invention include, e.g., a PDE7 inhibitor and an opioid agonist or a mixed opioid antagonist/partial antagonist.
  • combinations to be administered in accordance with the present invention include, e.g., a PDE7 inhibitor and an antidepressant or a PDE7 inhibitor and an agent affecting dopamine neurotransmission, e.g., a direct or indirect dopamine antagonist.
  • the effective amount of either or both of a PDE7 inhibitor and an additional therapeutic agent may be reduced when administered in combination than when either is provided alone.
  • a lower amount of the PDE7 inhibitor, a lower amount of the additional therapeutic agent, or lower amounts of both the PDE7 inhibitor or the additional therapeutic agent may be required to achieve the same therapeutic effect that would be provided by either the PDE7 inhibitor or the additional therapeutic agent alone.
  • An opioid antagonist acts on one or more opioid receptors. At least three types of opioid receptors, mu, kappa, and delta opioid receptors, have been reported, and opioid antagonists are generally classified by their effects on the opioid receptors. Opioid antagonists may antagonize central receptors, peripheral receptors or both. Naloxone and naltrexone are commonly used opioid antagonist drugs that are competitive in that they bind to the opioid receptors with higher affinity than agonists, but do not activate the receptors. This effectively blocks the receptor, preventing the body from responding to opiates and endorphins.
  • opioid antagonists are not pure antagonists but also produce some weak opioid partial agonist effects, and can produce analgesic effects when administered in high doses to opioid-naive individuals.
  • examples of such compounds include nalorphine, and levallorphan.
  • the analgesic effects from these drugs are limited and tend to be accompanied by dysphoria, most likely due to action at the kappa opioid receptor. Since they induce opioid withdrawal effects in people who are taking, or have previously used, opioid full agonists, these drugs are considered to be antagonists.
  • Naloxone is one example of an opioid antagonist that has no partial agonist effects. Instead, it is a weak inverse agonist at mu opioid receptors, and is used for treating opioid overdose.
  • opioid antagonists that may be used according to the invention include alvimopan, binaltorphimine, buprenorphine, cyclazocine, cyclorphan, cypridime, dinicotinate, beta-funaltrexamine, levallorphan, methylnaltrexone, nalbuphine, nalide, nalmefene, nalmexone, nalorphine, nalorphine dinicotinate, naloxone, naloxonazine, naltrendol, naltrexone, naltrindole, oxilorphan, and pentazocine.
  • Antidepressents are drugs used to treat depression.
  • the three neurotransmitters believed to be involved in depression are serotonin, dopamine, and norepinephrine.
  • Certain types of antidepressants increase the levels of one or more of these neurotransmitters in the brain by blocking their reabsorption.
  • SSRIs selective serotonin reuptake inhibitors
  • SNRIs tricyclic and tetracyclic serotonin and norepinephrine reuptake inhibitors
  • NRIs norepinephrine reuptake inhibitors
  • NDRIs norepinephrine and dopamine reuptake inhibitors
  • MAOIs monoamine oxidase inhibitors
  • SSRIs include, e.g., cericlamine, citalopram, clomipramine, cyanodothiepin, dapoxetine, duloxetine, escitalopram, femoxetine, fluoxetine, fluvoxamine, ifoxetine, imipramine, indalpine, indeloxazine, litoxetine, lofepramine, mianserine, milnacipran, mirtazapine, nefazadone, nortriptyline, paroxetine, sertraline, sibutramine, tomoxetine, trazodone, venlafaxine, and zimeldine.
  • SNRIs include, e.g., amoxapine, atomoxetine, bicifadine, desipramine, desvenlafaxine, duloxetine, maprotiline, milnacipran, nefazodone, reboxetine, sibutramine, and venlafaxine.
  • Nisoxetine, nortriptyline, reboxetine, talsupram, and tomoxetine are all examples of NRIs.
  • NDRIs include, e.g., bupropion, hydroxybupropion, and tesofensine.
  • Azaspirones include, e.g., buspirone, gepirone, ipsapirone, tandospirone, and tiaspirone.
  • Buspirone is an anxiolytic (partial agonist at 5-HT1 autoreceptors) that may be provided with an anti-depressant such as an SSRI.
  • MAOIs include, e.g., amiflamine, brofaromine, clorgyline, alpha-ethyltryptamine, iproclozide, iproniazid, isocarboxazid, mebanazine, moclobemide, nialamide, pargyline, phenelzine, pheniprazine, pirlindole, safrazine, selegiline, toloxatone, and tranlcypromine.
  • Atypical antidepressants include, e.g., amesergide, amineptine, benactyzine, bupropion, clozapine, fezolamine, levoprotiline, lithium, medifoxamine, mianserin, minaprine, olanzapine, oxaflozane, oxitriptan, rolipram, teniloxazine, tofenacin, trazodone, tryptophan, and viloxazine.
  • the anticonvulsants also called anti-epileptic drugs (AEDs) are a diverse group of drugs used in prevention of the occurrence of epileptic seizures and bipolar disorders. AEDs suppress the rapid and excessive firing of neurons that begins a seizure and/or prevents the spread of the seizure within the brain and offer protection against possible excitotoxic effects that may result in brain damage. Many anticonvulsants block sodium channels, calcium channels, AMPA receptors, or NMDA receptors.
  • Anti-epileptic agents include, but are not limited to, benzodiazepines, barbituates, valproates, GABA agents, iminostilibenes, hydantoins, NMDA antagonists, sodium channel blockers and succinamides.
  • Benzodiazepines include, e.g., alprazolam, chlordiazepoxide, cholrazepate, clobazam, clonazepam, diazepam, halazapam, lorazepam, oxazepam, and prazepam.
  • Barbiturates used as anti-epileptics include, e.g., amobarbital, mepobarbital, methylphenobarbital, pentobarbital, phenobarbital, and primidone.
  • Valproates used as anti-epileptics include, e.g., sodium valporate, valproic acid, valproate semisodium, and valpromide.
  • Anti-epileptic GABA agents include, e.g., gabapentin, losigamone, pregabalin, retigabine, rufinamide, and vigabatrin.
  • Carbamazepine and oxcarbazepine are examples of iminostilbenes.
  • Hydantoins include, e.g., fosphenyloin sodium, mephenyloin, and phenyloin sodium.
  • NMDA antagonists such as harkoseramide are used as anti-epileptics.
  • Sodium channel blockers such as lamotrigine are also anti-epileptic agents.
  • Succinimides include, e.g., ethosuximide, methsuximide, and phensuximide.
  • anti-epileptic drugs include acetazolamide, briveracetam, CBD cannabis derivative, clomthiazole edisilate, divalproex sodium, felbamate, isovaleramide, lacosamide, lamotrigine, levetiracetam, methanesulphonamide, talampanel, tiagabine, topiramate, safinamide, seletracetam, soretolide, stiripentol, sultiam, valrocemide, and zonisamide.
  • Antiemetics are drugs effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anesthetics, and chemotherapy.
  • Classifications of antiemetics include, e.g., 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, histamine receptor antagonists, dopamine receptor antagonists, muscarinic receptor antagonists, acetyl choline receptor antagonists, cannabinoid receptor antagonists, limbic system inhibitors, NK-1 receptor antagonists, corticosteroids, tachykinin antagonists, GABA agonists, cannabinoids, benzodiazepines, anticholinergics, and substance P inhibitors.
  • 5-hydroxytryptamine 3 (5-HT3) receptor antagonists e.g., 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, histamine receptor antagonists, dopamine receptor antagonists, muscarinic receptor antagonists, acetyl choline receptor antagonists, cannabinoid receptor antagonists, limbic system inhibitors, NK-1 receptor antagonists, corticosteroids, tachykinin antagonists, GABA agonists, cannabinoids
  • 5-HT3 receptor antagonists include, e.g., alosetron, azasetron, bemesetron, cilansetron, dolasetron, granisetron, indisetron, itasetron, ondansetron, palonosetron, propisetron, ramosetron, renzapride, tropisetron, and zatosetron.
  • Coritcosteroid antiemetics include dexamethasone and methylprednisolone.
  • Lymbic system inhibitors include alprazolam, lorazepam, and midazolam.
  • Dopamine receptor antagonists include diphenhydramine, dronabinol, haloperidol, metoclopramide, and prochlorperazine.
  • NK-1 receptor antagonists used as an antiemetic include aprepitant and morpholine, and an example of a GABA agonist is propofol.
  • Thiethylperazine is a type of histamine receptor antagonist.
  • Cannabinoid receptor antagonists or agonists used as antiemetics include dronabinol, nabilone, rimonabant,about, and tetrahydrocannabinol.
  • antiemetics examples include acetylleucine, monoethanolamine, alizapride, benzquinamide, bietanautine, bromopride, buclizine, chlorpromazine, clebopride, cyclizine, dimenhydrinate, dipheniodol, domperidone, dranisetron, meclizine, methalltal, metopimazine, oxypendyl, pipamazine, piprinhydrinate, scopolamine, thioproperzaine, and trimethobenzamide.
  • the cannabinoid receptors are a class of the G-protein coupled receptor superfamily. Their ligands are known as cannabinoids. There are currently two known subtypes, CB1 which is expressed mainly in the brain, but also in the lungs, liver, and kidney, and CB2, which is mainly expressed in the immune system and in hematopoietic cells. It is also believed that there are novel cannabinoid receptors that is, non-CB1 and non-CB2, which are expressed in endothelial cells and in the CNS. Cannabinoid receptor antagonists may be selective for either the CB1 or CB2 receptor. The present invention contemplates the use of either or both CB1 and CB2 receptor antagonists.
  • Addictive agents e.g., alcohol, opiates, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and psychostimulants, including nicotine
  • Addictive agents e.g., alcohol, opiates, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and psychostimulants, including nicotine
  • they share the common property of activating mesolimbic dopamine brain reward systems, and virtually all abused drugs elevate dopamine levels in the nucleus accumbens.
  • Cannabinoid-1 (CB1) receptors are expressed in this brain reward circuit and modulate the dopamine-releasing effects of Delta(9)-THC and nicotine.
  • Rimonabant (SR141716), a CB1 receptor antagonist, blocks both the dopamine-releasing and the discriminative and rewarding effects of Delta(9)-THC in animals.
  • CB1 receptor blockade is generally ineffective in reducing the self-administration of cocaine in rodents and primates, it reduces the reinstatement of extinguished cocaine-seeking behavior produced by cocaine-associated conditioned stimuli and cocaine priming injections.
  • CB1 receptor blockade is effective in reducing nicotine-seeking behavior induced by re-exposure to nicotine-associated stimuli.
  • rimonabant was shown to block the subjective effects of Delta(9)-THC in humans and prevents relapse to smoking in ex-smokers.
  • cannabinoid receptor CB1 antagonists include SR141716A (rimonabant), rosanabant, taranabant and CP-945598.
  • Relapse use, or reinstatement refers to the process of returning to the use of alcohol or another addictive agent or the practice of an addictive behavior after a period of abstinence from, or limited or reduced use of, an addictive agent or practice of an addictive behavior.
  • relapse use of an addictive agent refers to the return to use of an addictive agent by a subject who has undergone physical withdrawal from the addictive agent. Typically, the subject will have undergone physical withdrawal from the addictive agent during a period of non-use or limited or reduced use of the addictive agent.
  • relapse use occurs in a subject who has previously undergone a treatment regime with an effective amount of an anti-addiction agent to reduce or eliminate use of an addictive agent, but who is no longer using an effective amount of the anti-addiction agent.
  • Anti-addictive agents include any and all agents used to treat or prevent addiction or withdrawal symptoms.
  • Alcoholism like many other addictions, is a chronic relapsing disorder characterized by high recidivism rates.
  • Two major factors triggering relapse behavior are stress and environmental conditioning experiences (O'Brien et al. 1997; Monti et al. 1993; Shaham et al. 1995), which probably facilitate relapse to alcohol-seeking via distinct brain mechanisms.
  • activation of the mesolimbic dopamine system via an opioid-dependent mechanism or via direct alterations in dopamine transmission in the basolateral nucleus of amygdala
  • seems to mediate the effect of drug-associated cues seems to mediate the effect of drug-associated cues (Liu and Wiess 2002; Ciccocioppo et al.
  • extrahypothalamic CRF within the bed nucleus of the stria terminalis and median raphe nucleus is likely to mediate stress-induced reinstatement of drug-seeking behavior (Erb et al 1998; Shaham et al. 1995; Lê et al. 2000).
  • HPA hypothalamic-pituitary-adrenal
  • CRF non-neuroendocrine corticotropin-releasing factor
  • the CeA is rich in CRF immunoreactive cell bodies, terminals, and receptors, and this neuronal CRF system has been implicated in the mediation of behavioral and emotional responses to stressful stimuli.
  • Changes in the regulation of the activity of the CRF system within the CeA may represent a critical neuroadaptive mechanism responsible for the development of dependence and compulsive drug-seeking behavior.
  • relapse risk involves multiple determinants that are likely to interact. For example, exposure to drug cues may augment vulnerability to relapse imparted by protracted withdrawal symptoms resulting from neuroadaptive changes in dependent individuals. Interactive effects exacerbating relapse risk may also exist between the motivating effects of stress and drug-related cues. Recent work addressing these issues has confirmed that additive interactions between the response-reinstating effects of ethanol-associated cues and stress can indeed be demonstrated, and that these effects are enhanced in rats with a history of ethanol dependence. (Liu and Weiss, Soc. Neurosci. Abstr. 26, 786 (2000)).
  • PDE7 inhibitors significantly reduce stress-induced relapse use of an addictive agent (Example 1). These data indicate, therefore, that PDE7 inhibitors have anti-relapse properties.
  • naltrexone reduces the urge to drink elicited by presentation of alcohol cues in human alcoholics (Monti et al. 1993, supra) and decreases the efficacy of an alcohol cue to reinstate extinguished responding at a previously drug-paired lever in rats (Katner et al. 1999, supra).
  • naltrexone does not reduce relapse behavior elicited by stress ((Le A. D. Psychopharmacology 1998).
  • the invention includes a method of treating or preventing relapse use of an addictive agent or practice of an addictive or compulsive behavior, comprising administering an effective amount of a PDE7 inhibitor to a subject who previously reduced or eliminated use of an addictive agent or practice of an addictive or compulsive behavior in response to exposure to an effective amount of another anti-addiction treatment, wherein the subject is no longer exposed to an effective amount of the anti-addiction treatment.
  • the anti-addiction treatment may be an anti-addiction drug or may be a non-pharmacologic therapy such as counseling, psychotherapy or hypnosis therapy.
  • the relapse use may be triggered by stress.
  • the subject is no longer exposed to an effective amount of an anti-addiction agent because the subject has become tolerant to the agent, such that the blood plasma concentration of the anti-addiction agent that was previously effective in treating the addiction is no longer effective.
  • the subject is no longer exposed to an effective amount of an anti-addiction agent because the subject is now exposed to a lower blood plasma concentration of the anti-addiction agent, and this lower blood plasma concentration is not effective.
  • the subject has undergone a period of abstinence from, or limited or reduced use of, the addictive agent or practice of the addictive or compulsive behavior.
  • This period of abstinence or limited or reduced use may be, e.g., at least 24 hours, at least 48 hours, at least 3 days, at least 5 days, at least one week, at least 2 weeks, at least 1 month, at least 2 months, at least 4 months, at least 6 months, at least 9 months, at least one year, at least 2 years, or at least 5 years.
  • the present invention includes a method of treating or preventing relapse use of an addictive agent, comprising providing a PDE7 inhibitor and an opioid antagonist to a subject who has undergone physiological withdrawal from the addictive agent.
  • the present invention includes a method of treating or preventing relapse use of an addictive agent, comprising administering a PDE7 inhibitor and a CB1 antagonist, e.g., disulfiram, topiramate, levetiracetam, SSRIs, or ondansetron, to a subject who has undergone physiological withdrawal from the addictive agent.
  • a PDE7 inhibitor and a CB1 antagonist e.g., disulfiram, topiramate, levetiracetam, SSRIs, or ondansetron
  • the relapse use is triggered by stress, an environmental conditioning factor, or both.
  • the methods of the present invention may be practiced in subjects addicted to a single addictive agent, they may also be used in subjects addicted to two or more addictive agents. Similarly, while these methods may be used to prevent relapse use of the addictive agent from which the subject has undergone withdrawal, they may also be adapted to prevent relapse use or the commencement of use of an addictive agent different than the one from which the subject has undergone physiological withdrawal.
  • the present invention has established the efficacy of using combinations of a PDE7 inhibitor, in combination with one or more additional therapeutic agents, such as opioid antagonists, antidepressants, antiepileptics, antiemetics, and CB1 receptor antagonists.
  • additional therapeutic agents such as opioid antagonists, antidepressants, antiepileptics, antiemetics, and CB1 receptor antagonists.
  • the present invention further includes compositions comprising one or more PDE7 inhibitors and one or more additional therapeutic agents, such as opioid antagonists, mixed opioid antagonists/partial agonist, antidepressants, antiepileptics, antiemetics, CRF1 receptor antagonists and CB1 receptor antagonists.
  • the composition comprises one PDE7 inhibitor and one additional therapeutic agent.
  • the additional therapeutic agent is an opioid antagonist or a mixed opioid antagonist/partial agonist.
  • the opioid antagonist is naltrexone.
  • the mixed opioid partial agonist/antagonist is buprenorphine.
  • the additional therapeutic agent is an antidepressant.
  • the antidepressant is bupropion.
  • the additional therapeutic agent is an antiepileptic, an antiemetic, or an opioid antagonist or a mixed opioid partial agonist/antagonist.
  • compositions of the present invention may be administered to a subject as a pharmaceutical composition or formulation.
  • pharmaceutical compositions of the present invention may be in any form which allows for the composition to be administered to a subject.
  • the composition may be in the form of a solid, liquid or gas (aerosol).
  • Typical routes of administration include, without limitation, oral, topical, parenteral, sublingual, rectal, vaginal, and intranasal.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, epidural, intrasternal injection or infusion techniques.
  • compositions used according to the present invention comprise a PDE7 inhibitor, another therapeutic agent, and a pharmaceutically acceptable diluent, excipient, or carrier.
  • “Pharmaceutically acceptable carriers” for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remingtons Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
  • sterile saline and phosphate buffered saline at physiological pH may be used.
  • Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition.
  • sodium benzoate, sorbic acid and esters of p hydroxybenzoic acid may be added as preservatives. Id. at 1449.
  • antioxidants and suspending agents may be used. Id.
  • compositions of the invention are generally formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a subject.
  • Compositions that will be administered to a subject may take the form of one or more dosage units, where for example, a tablet, capsule or cachet may be a single dosage unit, and a container comprising a combination of agents according to the present invention in aerosol form may hold a plurality of dosage units.
  • the composition comprising a PDE7 inhibitor and another therapeutic agent is administered in one or more doses of a tablet formulation, typically for oral administration.
  • the tablet formulation may be, e.g., an immediate release formulation, a controlled-release formulation, or an extended-release formulation.
  • a tablet formulation comprises an effective amount of a composition comprising a PDE7 inhibitor and another therapeutic agent.
  • a tablet comprises about 1, 5, 10, 20, 30, 50 100, 150, 200, 250, or 300 mg of a PDE7 inhibitor, and about 1, 5, 10, 20, 30, 50 100, 150, 200, 250, or 300 mg of another therapeutic agent.
  • the present invention further includes unit-dosage forms of pharmaceutical compositions comprising a PDE7 inhibitor and another therapeutic agent.
  • Each unit-dosage form comprises a therapeutically effective amount of a pharmaceutical composition of the present invention, when used in the recommended amount.
  • a unit-dosage form may include a therapeutically effective amount in a single tablet, or a unit-dosage form may include a therapeutically effective amount in two or more tablets, such that the prescribed amount comprises a therapeutically effective amount.
  • a PDE7 inhibitor is provided to a subject in an amount in the range of 0.1-1000 mg/day, 1-1000 mg/day, 10-100 mg/day, or 25-50 mg/day.
  • pioglitazone is provided to a patient at about 30 mg/day.
  • kits comprising one or more unit dosage forms of a PDE7 inhibitor and one or more unit dosage forms of another therapeutic agent, such that the two unit dosage forms may be provided to a subject in a therapeutically effective manner.
  • the present invention includes a kit comprising unit-dosage forms of a PDE7 inhibitor and unit-dosage forms of nicotine.
  • the unit dosage forms of nicotine comprise a plurality of different unit-dosage forms of nicotine, wherein the different dosage forms of nicotine represent decreasing amount that may be taken one after the other over a period of time, so as to overcome addiction and effectuate withdrawal from the nicotine.
  • the unit-dosage forms of nicotine may be present, e.g., in the form of a transdermal patch, gum, or a lozenge.
  • Cyclic nucleotide phosphodiesterase type 7 is identified as a unique family based on its primary amino acid sequence and distinct enzymatic activity.
  • the PDE7 enzyme selectively decomposes cAMP and is characterized as an enzyme that is not inhibited by rolipram, a selective inhibitor of PDE4, which is a distinct, cAMP-specific PDE family.
  • PDE7A Meset al., J Biol. Chem. 268(17):12925-12932, 1993; Han, P., et al., J. Biol. Chem. 272(26):16152-16157, 1997) and PDE7B (U.S. Pat. No. 6,146,876; Gardner, C., et al., Biochem. Biophys. Res. Commun. 272(1):186-192, 2000; and Saski, T., et al., Biochem. Biophys. Res. Commun. 271(3):575-583, 2000).
  • the two gene products exhibit 70% identity in their C-terminal catalytic domains (Hetman J. M., et al., PNAS 97(1):472-476 (2000).
  • PDE7A has three splice variants (PDE7A1, PDE7A2 and PDE7A3); these variants are generated via alternative splicing at both the N- and C-termini (Bloom, T. J., and J. A. Beavo, Proc. Natl. Acad. Sci. USA. 93:14188-14192, 1996).
  • the nucleotide sequence of PDE7A, transcript variant 1 is accessible in public databases by the accession number NM — 002603.
  • Human PDE7A1 protein (SEQ ID NO: 2, encoded by SEQ ID NO:1) has 456 amino acids and migrates at an apparent molecular weight of 53-55 kDa on reduced SDS-PAGE.
  • PDE7A transcript variant 2
  • Human PDE7A2 protein (SEQ ID NO:4, encoded by SEQ ID NO:3) has 424 amino acids.
  • the PDE7A protein has a region of about 270 amino acids at the carboxy terminal end that displays significant similarity ( ⁇ 23% homology) to the analogous regions of other cAMP-hydrolyzing PDEs. This region serves as the catalytic domain. The amino-terminal region of this protein is divergent from that of other PDEs and presumably mediates the distinctive and regulatory properties unique to this enzyme family.
  • PDE7B The protein sequence of human PDE7B is accessible in public databases by the accession number NM — 018945, provided as SEQ ID NO:6, encoded by SEQ ID NO:5. Three splice variants of PDE7B have been reported: PDE7B1, PDE7B2 and PDE7B3. PDE7B is published in WO 01/62904, U.S. Pat. No. 6,146,876.
  • PDE7B2 and PDE7B3 possess unique N-terminal sequences.
  • Human PDE7B gene products have an apparent molecular weight of 53-55 kDa on reduced SDS-PAGE (Sasaki, T., Kotera, J., Omori, K., Biochemical J. 361:211-220, 2002).
  • the PDE7B has a significantly conserved region of about 270 amino acids common to all PDEs at the carboxy terminal, which serves as the catalytic domain. Similar to the PDE7A protein, the amino-terminal region of PDE7B protein is divergent and presumably accounts for the distinctive and regulatory properties unique to the individual PDE families.
  • the PDE7B protein shows homology to other cAMP-dependent PDEs (23%) within the catalytic domain.
  • the PDE7B polypeptide is 61% homologous to PDE7A, according to WO 2004/044196.
  • PDE7 is also uniquely localized in mammalian subjects relative to other PDE families.
  • PDE7A expression has been detected in the majority of tissues analyzed, including the brain, heart, kidney, skeletal muscle, spleen and uterus (Bloom, et al., PNAS 93:14188, 1996). Within the brain, PDE7A is widely distributed in both neuronal and non-neuronal cell populations (Miro, et al., Synapse 40:201, 2001).
  • PDE7A's wide expression in the brain, including the basal ganglia and substantia nigra provides a theoretical basis for a role for PDE7A in brain functions.
  • representative PDE7 inhibitory agents that inhibit the phosphodiesterase activity of PDE7 include: molecules that bind to PDE7 and inhibit the enzyme activity of PDE7 (such as small molecule inhibitors or blocking peptides that bind to PDE7 and reduce enzymatic activity), and molecules that decrease the expression of PDE7 at the transcriptional and/or translational level (such as PDE7 antisense nucleic acid molecules, PDE7 specific RNAi molecules and PDE7 ribozymes), thereby preventing PDE7 from cleaving cAMP.
  • the PDE7 inhibitory agents can be used alone as a primary therapy or in combination with other therapeutics (such as dopamine receptor agonists) as an adjuvant therapy to enhance the therapeutic benefits, as discussed supra.
  • the inhibition of PDE7 is characterized by at least one of the following changes that occur as a result of administration of a PDE7 inhibitory agent in accordance with the methods of the invention: the inhibition of PDE7-dependent enzymatic cleavage of the 3′-phosphodiester bond in cAMP to form 5′-adenosine monophosphate (5′-AMP), a reduction in the gene or protein expression level of PDE7, measured, for example, by gene expression analysis (e.g., RT-PCR analysis) or protein analysis (e.g., Western blot).
  • gene expression analysis e.g., RT-PCR analysis
  • protein analysis e.g., Western blot
  • a PDE7 inhibitory agent is a molecule or composition that inhibits the expression of PDE7A, PDE7B, or both PDE7A and PDE7B, such as an antisense or small inhibitory nucleotide (e.g., siRNA) that specifically hybridizes with the cellular mRNA and/or genomic DNA corresponding to the gene(s) of the target PDE7 so as to inhibit their transcription and/or translation, or a ribozyme that specifically cleaves the mRNA of a target PDE7.
  • an antisense or small inhibitory nucleotide e.g., siRNA
  • a PDE7 inhibitory agent useful in the methods of the invention is a compound that is sufficiently potent to inhibit the enzymatic activity of PDE7 (PDE7A, PDE7B, or PDE7A and PDE7B) at an IC 50 ⁇ 1 ⁇ M, preferably less than or about 0.1 ⁇ M.
  • the PDE7 inhibitory agent is sufficiently potent to inhibit the enzymatic activity of PDE7 (PDE7A, PDE7B, or PDE7A and PDE7B) at an IC 50 of from about 0.1 to about 500 nM.
  • the PDE7 inhibitory agent is potent to inhibit the enzymatic activity of PDE7 (PDE7A, PDE7B, or PDE7A and PDE7B) at an IC 50 of from about 1 to about 100 nM.
  • PDE7A or PDE7B inhibitory agent Representative methods for determining the IC 50 for a PDE7 (PDE7A or PDE7B) inhibitory agent are well known in the art, such as the Scintillation Proximity Assay (SPA) disclosed in Bardelle et al., Anal Biochem 15:275(2):148-55 (1999).
  • SPA Scintillation Proximity Assay
  • the PDE7 inhibitor useful in the method of the invention is a PDE7A inhibitory agent.
  • the PDE7A inhibitory agent is potent to inhibit the enzymatic activity of PDE7A at an IC 50 of from about 0.1 to about 500 nM.
  • the PDE7A inhibitor has an IC 50 of from about 1 to about 100 nM.
  • a suitable assay for determining the IC 50 for a PDE7A inhibitor uses recombinant human PDE7A2 enzymes expressed in a baculoviral system. This assay method is a modification of the SPA assay reported by Bardelle et al. supra.
  • the PDE7 inhibitory agent exhibits isozyme-selective activity against PDE7A.
  • a PDE7A selective inhibitory agent reduces PDE7A activity at least two-fold more than PDE7B activity, more preferably at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold.
  • the PDE7A inhibitory agent is an inhibitory agent that is at least 10-fold (such as at least 20-fold, or at least 50-fold or at least 100-fold) more selective for inhibiting PDE 7A activity than for the enzyme activity of any other PDE (PDE1-6, 7B, and 8-11).
  • the PDE7B inhibitor has an IC 50 of from about 0.1 to about 500 nM. In one embodiment, the PDE7B inhibitory agent is sufficiently potent to inhibit the enzymatic activity of PDE7B at an IC 50 of from about 0.1 to about 500 nM. In one embodiment, the PDE7B inhibitor has an IC 50 of from about 1 to about 100 nM. Methods for determining the IC 50 for a PDE7B inhibitor are well known in the art, such as the assays disclosed in Bardelle et al., supra.
  • the PDE7 inhibitor exhibits isozyme-selective activity against PDE7B.
  • a PDE7B selective inhibitory agent reduces PDE7B activity at least two-fold more than PDE7A activity, more preferably at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold.
  • the PDE7B inhibitory agent is an inhibitory agent that is at least 10-fold (such as at least 20-fold, or at least 50-fold or at least 100-fold) more selective for inhibiting PDE7B activity than for the enzyme activity of any other PDE (PDE1-6, 7A, and 8-11).
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE1B activity of greater than 5 times (such as at least 10-fold, at least 20-fold, or at least 50-fold or at least 100-fold) the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitor is more potent (by 5 times, 10 times, 20 times, 50 times or 100 times) at inhibiting the activity of PDE7A or PDE7B (whichever PDE7A or PDE7B isozyme upon which the PDE7 inhibitor has the most effect), than it is at inhibiting the activity of PDE1B.
  • this property may be still more simply stated as the PDE7 inhibitor is more potent (by 5 times, 10 times, 20 times, 50 times or 100 times) at inhibiting the activity of PDE7 than it is at inhibiting the activity of PDE1B.
  • Dual inhibition of both PDE7 and PDE1B may confer additional benefit in the treatment of movement disorders based on a report that deletion of the gene for PDE1B in mice stimulated the metabolism of dopamine and sensitized the animals to the effects of dopaminergic agonists (Siuciak, et al., Neuropharmacology 53(1): 113-23 (2007)).
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE10 activity of greater than 5 times (such as at least 10-fold, or at least 20-fold, or at least 50-fold or at least 100-fold) the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • Dual inhibition of both PDE7 and PDE10 may confer additional benefit in the treatment of movement disorders based on a report that selective inhibitors of PDE10 cause an increase in cAMP levels in the striatum (Siuciak J. A. et al., Neuropharmacology 51(2):386-96 (2006)).
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE3 activity of greater than 10 times (such as at least 20-fold, at least 50-fold or at least 100-fold) the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity. This is because the administration of selective inhibitors of PDE3 to patients in heart failure was shown to increase their rate of mortality (Packer M. et al., N Engl J. Med. 325(21):1468-75 (1991)).
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE4 activity of greater than 10 times (such as at least 20-fold, at least 50-fold or at least 100-fold) the lesser of the IC 50 for inhibiting PDE7A activity and the 1050 for inhibiting PDE7B activity. This is because deletion of one of the PDE4 genes in mice has been shown to lead to cardiac myopathy (Lehnart S. E. et al., Cell 123(1):25-35 (2005)).
  • the PDE7 inhibitory agent has a half maximally effective dose (“ED 50 ”) in an in vivo assay of PDE4 inhibition (for example, sedation or inhibition of TNF alpha levels after endotoxin treatment) of greater than 10 times (such as at least 20-fold, at least 50-fold or at least 100-fold) the lesser of the ED 50 in an in vivo assay of PDE7A and PDE7B inhibition (for example, prevention of relapse to cocaine or other psychostimulant addiction).
  • ED 50 half maximally effective dose
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE3 activity and PDE4 activity of greater than 10 times (such as at least 20-fold, at least 50-fold or at least 100-fold) the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE8 activity of greater than 10 times (such as at least 20-fold, at least 50-fold or at least 100-fold) the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting PDE4 activity and PDE8 activity of greater than 10 times (such as at least 20-fold, at least 50-fold or at least 100-fold) the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • PDE families that specifically/preferentially hydrolyze cAMP include PDE4, PDE7, and PDE8.
  • the PDE7 inhibitory agent has an IC 50 for inhibiting the activity of PDE1, PDE2, PDE3, PDE4, and PDE8, PDE10, and PDE11 of greater than 10 times the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity.
  • PDE families that specifically/preferentially hydrolyze cAMP include PDE4, PDE7, and PDE8 and the PDE1, PDE2, PDE3, PDE10, and PDE11 families show substantial activity against both cAMP and cGMP.
  • the PDE inhibitory agent is a selective PDE7 inhibitor for which the lesser of the IC 50 for inhibiting PDE7A activity and the IC 50 for inhibiting PDE7B activity is less than one-tenth (such as one-twentieth, one-fiftieth, or one-hundredth) the IC 50 that the agent has for inhibiting any other PDE enzyme from the PDE1-6 and PDE8-11 enzyme families.
  • a selective PDE7 inhibitor can be identified, for example, by comparing the ability of an agent to inhibit PDE7 (PDE7A, PDE7B or PDE7A and PDE7B) enzyme activity to its ability to inhibit PDE enzymes from the other PDE families. For example, an agent may be assayed for its ability to inhibit PDE7 activity as well as PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE8, PDE9, PDE10, and PDE11.
  • the ratio of the IC 50 inhibition for each of the PDE (1-6 and 8-11) isozymes to the IC 50 inhibition of PDE7 may be determined by a standard in vitro, in vivo, or ex vivo assay, such as those described herein.
  • a PDE7 inhibitor is selective for PDE7 and substantially inactive against other PDEs (e.g., PDE1, PDE2, PDE3, PDE4, and PDE8, PDE10, and PDE11) due to targeting of the PDE7 inhibitor to one or more target tissues, such as the brain and/or skeletal muscle.
  • PDE7 is uniquely localized in mammalian subjects relative to other PDE families.
  • PDE7A is widely distributed in both neuronal and non-neuronal cell populations, including the basal ganglia and substantia nigra (Miro et al., Synapse 40:201, 2001).
  • PDE7B is expressed in the brain in the striatum (Reyes-Irisarri et al., Neuroscience 132:1173, 2005).
  • the PDE7 inhibitory agent can be any type of agent including, but not limited to, a chemical compound, a protein or polypeptide, a peptidomimetic, a nucleic acid molecule, or ribozyme.
  • PDE7 inhibitory agents are small molecule inhibitors including natural and synthetic substances that have a low molecular weight (i.e., less than about 450 g/mole), such as, for example, peptides, peptidomimetics and nonpeptide inhibitors such as chemical compounds.
  • the PDE7 inhibitors useful in the methods of the invention include agents that are administered by a conventional route (e.g., oral, intramuscular, subcutaneous, transdermal, transbucal, intravenous, etc.) into the bloodstream and are ultimately transported through the vascular system across the blood brain barrier to inhibit PDE7 in the brain. Accordingly, for these methods of administration, the PDE7 inhibitors have the ability to cross the blood brain barrier.
  • a conventional route e.g., oral, intramuscular, subcutaneous, transdermal, transbucal, intravenous, etc.
  • the PDE7 inhibitors have the ability to cross the blood brain barrier.
  • those PDE inhibitors described below that have the ability to cross the blood brain barrier are useful in the methods of the invention when the inhibitors are administered by a route that ultimately transports the inhibitors to the brain in the bloodstream.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in EP 1 454 897, WO 2003/053975, and US 20050148604, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • A represents N or CR 4 ,
  • B represents a hydrogen atom or a halogen atom
  • R 1 represents optionally substituted C 3-7 cycloalkyl or tert-butyl
  • R 2 represents hydrogen, methyl, or ethyl
  • R 3 represents a hydrogen, nitro, cyano or halogen atom, NR 5 R 6 , C( ⁇ X)R 7 , SO 2 NR 5 R 6 , OR 8 , NR 8 CONR 5 R 6 , NR 8 SO 2 R 9 , NR 8 CO 2 R 9 , a heteroaryl group, optionally substituted C 1-3 alkyl, optionally substituted C 1-6 alkenyl, or optionally substituted saturated or unsaturated heterocycloalkyl,
  • R 4 represents hydrogen, or C 1-3 alkoxy substituted, if desired, by one or more fluorine atoms,
  • R 5 and R 6 are the same or different, and represent a hydrogen atom, optionally substituted C 1-6 alkyl, optionally substituted heterocycloalkyl, or optionally substituted acyl or, together with the nitrogen atom which they are bound to, form azetidinyl, pyrrolidinyl, piperidinyl, morpholino, thiomorpholino, piperazinyl, or homopiperazinyl, each of these groups being optionally substituted by optionally substituted C 1-4 alkyl, OH, C 1-3 alkoxy, CO 2 H, NR 5 R 6 , an oxo group, NR 9 COR 7 , or C( ⁇ O)R 7 ,
  • R 7 represents optionally substituted C 1-6 alkyl, OH, OR 8 , or NR 5 R 6 ,
  • R 8 represents hydrogen, an optionally substituted C 1-6 alkyl group, or optionally substituted heterocycloalkyl,
  • R 9 represents an optionally substituted C 1-6 alkyl group
  • X represents O, S, or NH.
  • optionally substituted refers to optionally substituted linear, branched or cyclic alkyl group such as methyl, ethyl, propyl or cyclohexyl; a hydroxyl group; a cyano group; an alkoxy group such as methoxy or ethoxy; an optionally substituted amino group such as amino, methylamino or dimethylamino; an optionally substituted acyl group such as acetyl or propionyl; a carboxyl group; an optionally substituted aryl group such as phenyl or naphthyl; an optionally substituted heteroaryl group such as pyridinyl, thiazolyl, imidazolyl or pyrazyl; an optionally substituted saturated or unsaturated heterocycloalkyl group such as piperazinyl or morphonyl; an optionally substituted carbamoyl group; an optionally substituted amido group; a halogen atom
  • heteroaryl group as R 3 examples include a 5- to 7-membered monocyclic heteroaryl group having 2 to 8 carbon atoms and containing 1 to 4 hetero atoms consisting of oxygen atoms, nitrogen atoms or sulfur atoms, and a polycyclic heteroaryl group comprising two or more such identical or different monocyclic compounds fused together, examples of the monocyclic and polycyclic heteroaryl groups being pyrrole, furyl, thienyl, imidazolyl, thiazolyl, pyridyl, pyrazyl, indolyl, quinolyl, isoquinolyl, and tetrazolyl.
  • a PDE7 inhibitor useful in the invention has the formula:
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • a PDE7 inhibitor useful in the methods of the invention has the formula:
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 2002/0198198, WO 2002/076953, WO 2002/074754, WO 2006/092691 , Bioorganic & Medicinal Chemistry Letters 14 (2004) 4623-4626, and Bioorganic & Medicinal Chemistry Letters 14 (2004) 4627-4631, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • X 1 , X 2 , X 3 , and X 4 are the same or different and are selected from:
  • N provided that not more than two of the groups X I , X 2 , X 3 , and X 4 simultaneously represent a nitrogen atom, or,
  • R 1 is selected from:
  • X is O, S, or NR 9 , in which R 9 is selected from hydrogen, CN, OH, NH 2 , lower alkyl, lower alkenyl, or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, aryl, heteroaryl, OR 10 , or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Y is selected from O, S, or N—R 12 , in which R 12 is selected from hydrogen, CN, OH, NH 2 , lower alkyl, lower alkenyl, or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, aryl, heteroaryl, OR 10 , or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Z is chosen from CH—NO 2 , O, S, or NR 13 in which R 13 is selected from hydrogen, CN, OH, NH 2 , aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, C( ⁇ O)R 14 , C( ⁇ O)NR 14 R 15 , OR 14 , or, lower alkyl, unsubstituted or substituted with one or several groups which are the same or different and which are selected OR 14 or NR 14 R 15 ;
  • Z 1 is chosen from H, CH 3 , or NR 16 R 17 in which R 16 and R 17 are the same or different and are selected from hydrogen, CN, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, C( ⁇ O)R 14 , C( ⁇ O)NR 14 R 15 , OR 14 , or, lower alkyl unsubstituted or substituted with one or several groups selected from OR 14 or NR 14 R 15 ,
  • A is a cycle selected from:
  • a 1 , A 2 , A 3 , A 1 , A 5 , and A 6 are the same or different and are selected from O, S, C, C( ⁇ O), SO, SO 2 , or NR 18 in which R 18 is selected from hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N, CN, NH 19 R 20 , C( ⁇ O)NR 19 R 20 , OR 19
  • * represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 , or CONR 21 R 22 , lower haloalkyl, CN, F, ⁇ O, SO 2 NR 19 R 20 , OR 19 , SR 19 , C( ⁇ O)OR 19 , C( ⁇ O)NR 19 R 20 , or NR 19 R 20 in which R 19 and R 20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 , or CONR 21 R 22 , in which R 21 and R 22 are identical or different and are selected from hydrogen or lower alkyl, and, R 19 and R 20 , and/or, R 21 and R 22 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • two atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N; provided that not more than two of the groups A 1 , A 2 , A 3 , A 4 , A 5 , and A 6 simultaneously represent a heteroatom; and
  • halogen includes fluoro, chloro, bromo, and iodo.
  • Preferred halogens are F and Cl.
  • Lower alkyl includes straight and branched carbon chains having from 1 to 6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, isopropyl, and tert-butyl.
  • Lower alkenyl includes straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and at least one double bond. Examples of such alkenyl groups are ethenyl, 3-buten-1-yl, 2-ethenylbutyl, and 3-hexen-1-yl.
  • Lower alkynyl includes straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and at least one triple bond. Examples of such alkynyl groups are ethynyl, 3-butyn-1-yl, propynyl, 2-butyn-1-yl, and 3-pentyn-1-yl.
  • Lower haloalkyl includes a lower alkyl as defined above, substituted with one or several halogens. An example of haloalkyl is trifluoromethyl.
  • Aryl is understood to refer to an aromatic carbocycle containing between 6 and 10 carbon atoms. An example of an aryl group is phenyl.
  • Heteroaryl includes aromatic cycles which have from 5 to 10 ring atoms, from 1 to 4 of which are independently selected from the group consisting of O, S, and N.
  • Representative heteroaryl groups have 1, 2, 3 or 4 heteroatoms in a 5- or 6-membered aromatic ring. Examples of such groups are tetrazole, pyridyl, and thienyl.
  • Representative cycloalkyl contain from 3 to 8 carbon atoms. Examples of such groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • interrupted means that in a backbone chain, a carbon atom is replaced by an heteroatom or a group as defined herein.
  • cycloalkyl or cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 heteroatom chosen from O, S, S( ⁇ O), SO 2 or N the term “interrupted” means that C( ⁇ O) or a heteroatom can replace a carbon atom of the ring.
  • Example of such groups are morpholine or piperazine.
  • Cycloalkenyl includes 3- to 10-membered cycloalkyl containing at least one double bond.
  • Heterocyclic rings include heteroaryl as defined above and cycloalkyl or cycloalkenyl, as defined above, interrupted with 1, 2 or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N.
  • Bicyclic substituents refer to two cycles, which are the same or different and which are chosen from aryl, heterocyclic ring, cycloalkyl or cycloalkenyl, fused together to form said bicyclic substituents.
  • An example of a bicyclic substituent is indolyl.
  • a PDE7 inhibitor useful in the methods of the invention has the formula:
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in EP 1 193 261, WO 2002/28847, US 20030045557, U.S. Pat. No. 7,122,565, Bioorganic & Medicinal Chemistry Letters 14 (2004) 4607-4613, and Bioorganic & Medicinal Chemistry Letters 14 (2004) 4615-4621, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • Y is S or O
  • R 1 is C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, or a polycyclic group; each optionally substituted with one or several groups X 1 —R 4 , identical or different, in which X 1 is a single bond, lower alkylene, C 2 -C 6 alkenylene, cycloalkylene, arylene, or divalent heterocycle, and R 4 is:
  • R 2 is lower alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, cycloalkyl, cycloalkenyl, heterocycle, aryl; each optionally substituted with one or several groups which are the same or different and which are selected from:
  • R 3 is X 2 —R′ 3 , wherein X 2 is a single bond or, a group selected from C 1 -C 4 alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, each optionally substituted with one or several groups which are the same or different and which are selected from:
  • R′ 3 is cycloalkyl, cycloalkenyl, aryl, heterocycle, or a polycyclic group; each optionally substituted with one or several groups X 3 —R 17 wherein X 3 is a single bond, lower alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, cycloalkylene, arylene, divalent heterocycle or a divalent polycyclic group, and, R 17 is:
  • R 5 and R 6 are the same or different and are selected from H, lower alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, X 4 -cycloalkyl, X 4 -cycloalkenyl, X 4 -aryl, X 4 -heterocycle or X 4 -polycyclic group, wherein X 4 is a single bond, lower alkylene, or C 2 -C 6 alkenylene; each optionally substituted with one or several groups that are the same or different and selected from halogen, ⁇ O, COOR 20 , CN, OR 20 , O-lower alkyl optionally substituted with OR 20 , C( ⁇ O)-lower alkyl, lower haloalkyl,
  • X 5 is a single bond or lower alkylene and R 18 , R 19 , and R 20 , are the same or different and are selected from H or lower alkyl;
  • R 9 is selected from H, CN, OH, lower alkyl, O-lower alkyl, aryl, heterocycle, SO 2 NH 2 , or
  • X 5 is a single bond or lower alkylene and R 18 and R 19 are the same or different and are selected from H or lower alkyl;
  • R 10 is selected from hydrogen, lower alkyl, cyclopropyl, or heterocycle
  • aryl refers to an unsaturated carbocycle, exclusively comprising carbon atoms in the cyclic structure, the number of which is between 5 and 10, including phenyl, naphthyl, or tetrahydronaphthyl.
  • Heterocycle refers to a nonsaturated or saturated monocycle containing between 1 and 7 carbon atoms in the cyclic structure and at least one heteroatom in the cyclic structure, such as nitrogen, oxygen, or sulfur, preferably from 1 to 4 heteroatoms, identical or different, selected from nitrogen, sulfur and oxygen atoms.
  • Suitable heterocycles include morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl, pyrimidinyl, 2- and 3-furanyl, 2- and 3-thienyl, 2-pyridyl, 2- and 3-pyranyl, hydroxypyridyl, pyrazolyl, isoxazolyl, tetrazole, imidazole, triazole, and the like.
  • Polycyclic groups include at least two cycles, identical or different, selected from aryl, heterocycle, cycloalkyl, cycloalkenyl groups fused together to form said polycyclic group such as 2- and 3-benzothienyl, 2- and 3-benzofuranyl, 2-indolyl, 2- and 3-quinolinyl, acridinyl, quinazolinyl, indolyl benzo[1,3]dioxolyl, and 9-thioxantanyl.
  • Bicyclic groups refer to two cycles, which are the same or different and which are chosen from aryl, heterocycle, cycloalkyl or cycloalkenyl, fused together to form said bicyclic groups.
  • Halogen refers to fluorine, chlorine, bromine, or iodine.
  • Lower alkyl refers to an alkyl is linear or branched and contains 1 to 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, isobutyl, n-butyl, pentyl, hexyl and the like.
  • Alkenyl refers to a linear or branched unsaturated carbon atom chain, comprising one or several double bonds, preferably one or two double bonds.
  • Alkynyl refers to a linear or branched unsaturated carbon atom chain, comprising one or several triple bonds, preferably one or two triple bonds.
  • Lower haloalkyl refers to a lower alkyl substituted with one or several halogens; preferred lower haloalkyl groups include perhaloalkyl groups such as CF 3 .
  • Cycloalkyl refers to saturated monocarbocyle containing from 3 to 10 carbon atoms; including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • Cycloalkenyl refers to unsaturated monocarbocyle containing from 3 to 10 carbon atoms. Examples of suitable cycloalkenyl are 3-cyclohexene, and 3-cycloheptene.
  • Carboxylic acid bioisostere has the classical meaning; common carboxylic acid bioisostere are tetrazole-5-yl, C( ⁇ O)N(H)OH, isoxazol-3-yl, hydroxythiadiazolyl, sulfonamido, sulfonylcarboxamido, phosphonic acid, phosphonamido, phosphinic acid, sulfonic acids, acyl sulfonamido, mercaptoazole, acyl cyanamides.
  • a PDE7 inhibitor useful in the methods of the invention has the formula:
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2004/111054, US 20060128728, and US 20070270419, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • R 1 is a substituted or unsubstituted C 3-8 cycloalkyl group or tert-butyl group;
  • R 2 is a hydrogen atom or C 1-3 alkyl group
  • R 3 is a group: NR 5 R 6 , C( ⁇ O)R 7 , or S(O) 0-2 R 8 ;
  • R 4 is a hydrogen atom or C 1-3 alkoxyl group which is unsubstituted or substituted by one or more fluorine atom(s);
  • R 5 and R 6 are, same or different from each other, a hydrogen atom, substituted or unsubstituted C 1-6 alkyl group, substituted or unsubstituted acyl group, substituted or unsubstituted heterocycloalkyl group, and substituted or unsubstituted heterocycloalkyl ring formed with a nitrogen atom which is binding R 5 and R 6 ;
  • R 7 is a group: OR 9 or NR 5 R 6 ;
  • R 8 is a hydrogen atom, a halogen atom, a group: NR 5 R 6 , substituted or unsubstituted C 1-6 alkyl group, or substituted or unsubstituted aryl group;
  • R 9 is a hydrogen atom or substituted or unsubstituted C 1-6 alkyl group
  • C 1 -C 3 alkyl group includes a straight or branched-chained alkyl group having 1 to 3 carbon atoms.
  • C 3 -C 8 cycloalkyl group includes a cycloalkyl group having 3 to 8 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclooctyl.
  • heterocycloalkyl group is 3 to 7 membered heterocyclic group containing the same or different 1 to 4 hetero atom(s) such as oxygen, nitrogen or sulfur atom(s), and examples may include pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, tetrahydrofuryl, tetrahydrophyranyl, morpholinyl and azetidinyl.
  • C 1 -C 3 alkoxy group means alkoxy group having 1 to 3 carbon atoms.
  • acyl group means acyl group having 1 to 8 carbon atoms.
  • aryl group is phenyl, naphthyl, biphenyl group, having 6 to 12 carbon atoms
  • heteroaryl group is 5 to 7 membered monocyclic or polycyclic group thereof containing 2 to 8 carbon atoms and the same or different 1 to 4 hetero atom(s) such as oxygen, nitrogen, sulfur atom(s).
  • the examples include pyrrole, furyl, thienyl, imidazolyl, thiazolyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl, tetrazolyl, pyridinyl, pyrazolyl pyridazinyl and pyrimidinyl.
  • substituent of “substituted or unsubstituted C 1 -C 6 alkyl group” include hydroxyl group and halogen atom
  • suitable substituent of “substituted or unsubstituted acyl group” include halogen atom and nitro group
  • suitable substituent of “substituted or unsubstituted aryl group” include C 1 -C 3 alkyl, halogen atom, amino group, acyl group, amide group, hydroxyl group, acylamino group, carboxyl group and sulfonyl group.
  • Examples of suitable substituent of “substituted or unsubstituted C 3 -C 8 cycloalkyl group” is C 1 -C 3 alkyl, hydroxyl group and oxo group
  • suitable substituent of “substituted or unsubstituted heterocycloalkyl group” may include carboxy group, acyl group, alkoxy group, amino group, alkylamino group, acylamino group, hydroxyl group, oxo group, ethylenedioxy group, methyl group, ethyl group and hydroxyethyl group.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,903,109, US 20040082578, WO 2003/088963, and US 20060154949, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 is selected from the group consisting of:
  • R 2 is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3-7 cycloalkyl, optionally substituted heterocyclyl, wherein the heterocyclyl is 1,3-dioxolane or furan, or R 2 is
  • R 3 is from one to four groups independently selected from the group consisting of:
  • R 4 is selected from the group consisting of (i) hydrogen, (ii) C 1-3 straight or branched chain alkyl, (iii) benzyl, and (iv) NR 13 R 14 , wherein R 13 and R 14 are independently selected from hydrogen and C 1-6 alkyl; wherein the C 1-3 alkyl and benzyl groups are optionally substituted with one or more groups selected from C 3-7 cycloalkyl, C 1-8 alkoxy, cyano, C 1-4 carboalkoxy, trifluoromethyl, C 1-8 alkylsulfonyl, halogen, nitro, hydroxy, trifluoromethoxy, C 1-8 carboxylate, amino, NR 13 R 14 , aryl, and heteroaryl; and
  • X is selected from S and O;
  • R 1 , R 3 , and R 4 are as above and R 2 is NR 15 R 16 , where R 15 and R 16 are independently selected from hydrogen, C 1-8 straight or branched chain alkyl, arylalkyl, C 3-7 cycloalkyl, aryl, heteroaryl, and heterocyclyl, or R 15 and R 16 taken together with the nitrogen to which they are attached form a heterocyclyl or heteroaryl group.
  • alkyl refers to straight, cyclic and branched-chain alkyl.
  • the alkyl group may be optionally substituted with one or more groups such as halogen, OH, CN, mercapto, nitro, amino, C 1 -C 8 -alkyl, C 1 -C 8 -alkoxyl, C 1 -C 8 -alkylthio, C 1 -C 8 -alkyl-amino, di(C 1 -C 8 -alkyl)amino, (mono-, di-, tri-, and per-) halo-alkyl, formyl, carboxy, alkoxycarbonyl, C 1 -C 8 -alkyl-CO—O-—, C 1 -C 8 -alkyl-CO—NH—, carboxamide, hydroxamic acid, sulfonamide, sulfonyl, thiol, aryl, aryl(c 1 -
  • bioisostere is defined as “groups or molecules which have chemical and physical properties producing broadly similar biological properties.” (Burger's Medicinal Chemistry and Drug Discovery, M. E. Wolff, ed. Fifth Edition, Vol. 1, 1995, Pg. 785).
  • acyl as used herein, whether used alone or as part of a substituent group, means an organic radical having 2 to 6 carbon atoms (branched or straight chain) derived from an organic acid by removal of the hydroxyl group.
  • “Aryl” or “Ar,” whether used alone or as part of a substituent group, is a carbocyclic aromatic radical including, but not limited to, phenyl, 1- or 2-naphthyl and the like.
  • the carbocyclic aromatic radical may be substituted by independent replacement of 1 to 5 of the hydrogen atoms thereon with halogen, OH, CN, mercapto, nitro, amino, C 1 -C 8 -alkyl, C 1 -C 8 -alkoxyl, C 1 -C 8 -alkylthio, C 1 -C 8 -alkyl-amino, di(C 1 -C 8 -alkyl)amino, (mono-, di-, tri-, and per-) halo-alkyl, formyl, carboxy, alkoxycarbonyl, C 1 -C 8 -alkyl-CO—O—, C 1 -C 8 -alkyl-CO—NH—, or carboxamide.
  • halogen OH, CN, mercapto, nitro, amino, C 1 -C 8 -alkyl, C 1 -C 8 -alkoxyl, C 1 -C 8 -alkylthi
  • Illustrative aryl radicals include, for example, phenyl, naphthyl, biphenyl, fluorophenyl, difluorophenyl, benzyl, benzoyloxyphenyl, carboethoxyphenyl, acetylphenyl, ethoxyphenyl, phenoxyphenyl, hydroxyphenyl, carboxyphenyl, trifluoromethyl phenyl, methoxyethylphenyl, acetamidophenyl, tolyl, xylyl, dimethylcarbamylphenyl and the like.
  • heteroaryl refers to a cyclic, fully unsaturated radical having from five to ten ring atoms of which one ring atom is selected from S, O, and N; 0-2 ring atoms are additional heteroatoms independently selected from S, O, and N; and the remaining ring atoms are carbon.
  • the radical may be joined to the rest of the molecule via any of the ring atoms.
  • heterocycle refers to an optionally substituted, fully or partially saturated cyclic group which is, for example, a 4- to 7-membered monocyclic, 7- to 11-membered bicyclic, or 10- to 15-membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom containing ring.
  • Each ring of the heterocyclic group containing a heteroatom may have 1, 2, or 3 heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized.
  • the nitrogen atoms may optionally be quaternized.
  • the heterocyclic group may be attached at any heteroatom or carbon atom.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,958,328, WO 2002/085894, and US 20030212089, each expressly incorporated herein by reference in its entirety.
  • These PDE7 inhibitors have the same formula as those described above (e.g., U.S. Pat. No. 6,903,109), except that R 1 is not a carboxylic ester or carboxylic acid bioisostere.
  • the preparation of these compounds is described in U.S. Pat. No. 6,958,328, US 20030212089, and WO 2002/085894.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2006/004040 and EP 1 775 298, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 is substituted or unsubstituted C 3-8 alkyl group, substituted or unsubstituted cycloalkyl group, or substituted or unsubstituted heterocycloalkyl group (e.g., cyclohexyl, cycloheptyl, or tetrahydropyranyl);
  • R 2 is a hydrogen atom or substituted or unsubstituted C 1-3 alkyl group (e.g., methyl);
  • R 3 is a hydrogen atom, substituted or unsubstituted C 1-3 alkyl group, or a halogen atom
  • R 4 is substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group CONR 5 R 6 , or CO 2 R 7 ,
  • R 5 and R 6 are, same or different from each other, a hydrogen atom; C 1-6 alkyl group which may be substituted by a halogen atom, substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted cycloalkyl group, a group NR 7 COR 8 , COR 8 , NR 9 R 10 ; substituted or unsubstituted cycloalkyl group; substituted or unsubstituted heterocycloalkyl group; substituted or unsubstituted aryl group; substituted or unsubstituted heteroaryl group; or substituted or unsubstituted heterocycloalkyl group in which the ring is formed together with the nitrogen atom binding R 5 and R 6 ;
  • R 7 is a hydrogen atom or substituted or unsubstituted C 1-3 alkyl group
  • R 8 is substituted or unsubstituted heterocycloalkyl group, or a group OH, OR 7 , or NR 9 R 10 ;
  • R 9 and R 10 are, same or different from each other, a hydrogen atom; substituted or unsubstituted C 1-3 alkyl group, substituted or unsubstituted heterocycloalkyl group; substituted or unsubstituted acyl; a group SO 2 R 7 , or substituted or unsubstituted heterocycloalkyl group in which the ring is formed together with the nitrogen atom binding R 5 and R 6 ;
  • cycloalkyl group means cycloalkyl group having 3 to 8 carbon atoms.
  • heterocycloalkyl group may be 3 to 7 membered monocyclic or polycyclic heterocyclic group containing the same or different 1 to 4 hetero atom(s) such as oxygen, nitrogen or sulfur atom(s), and examples may include piperidinyl, pyrrolidinyl, piperazinyl, tetrahydrofuryl, tetrahydropyranyl, morpholinyl, azetidinyl, imidazolidinyl, oxazolidinyl, hexahydropyrrolidinyl, octahydroindolidinyl, octahydroquinolidinyl, octahydroindolyl, and oxo-derivatives thereof.
  • aryl group may be aromatic hydrocarbon group, which consists of mono-benzene ring, or binding or condensed benzene ring, such as phenyl, naphthyl, biphenyl and the like; and dicyclic or tricyclic group, which consists of benzene ring condensed with cycloalkyl or heterocyclic ring, such as 1,2,3,4-tetrahydronaphthalene, 2,3-dihydroindene, indoline, coumarone and the like.
  • heteroaryl group may be 5 to 7 membered monocyclic heteroaryl group or polycyclic heteroaryl group, and having 2 to 8 carbon atoms with 1 to 4 hetero atom(s) such as oxygen, nitrogen, sulfur atom(s), in which the polycyclic heteroaryl group has condensed ring system by the same or different monocyclic heteroaryl or benzene ring each other; or polycyclic group which is consisted of heteroaryl group condensed with cycloalkyl or heterocycloalkyl ring.
  • substituent of the present invention may include straight, branched-chained or cyclic C 1 -C 8 alkyl group, which may be substituted by one or more methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, cyclohexyl, cycloheptyl, methoxymethyl, hydroxymethyl, trifluoromethyl, C 1 -C 3 alkoxy group, halogen atom, and hydroxyl group; hydroxyl group; cyano group; substituted or unsubstituted alkoxy group such as methoxy, ethoxy group; amino group which may be substituted by C 1 -C 6 alkyl group or acyl group such as amino, methylamino, ethylamino, dimethylamino, acylamino and the like; carboxylic group; substituted or unsubstituted ester group; phosphate group; sulfonic group; substituted or
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2004/111053 and US 20060128707, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • A is N or CR 4 ;
  • B is N or CH
  • R 1 is substituted or unsubstituted C 3-8 cycloalkyl group or tert-butyl group
  • R 2 is a hydrogen atom or C 1-6 alkyl group
  • R 3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C 1-6 alkyl group; substituted or unsubstituted C 2-6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: NR 5 R 6 , C(O)R 7 , SO 2 R 7 , OR 8 , NR 8 COR 7 , NR 8 SO 2 R 7 ;
  • R 4 is a hydrogen atom or C 1-3 alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);
  • R 5 and R 6 are, same or different from each other, a hydrogen atom; substituted or unsubstituted C 1-6 alkyl group; substituted or unsubstituted acyl group; or substituted or unsubstituted heterocycloalkyl group;
  • R 7 is a hydrogen atom; substituted or unsubstituted C 1-6 alkyl group; substituted or unsubstituted heterocycloalkyl group; OH; OR 8 or NR 5 R 6 ;
  • R 8 is a hydrogen atom, substituted or unsubstituted C 1-6 alkyl group; or substituted or unsubstituted heterocycloalkyl group;
  • C 1 -C 6 alkyl group refers to a straight or branched-chained alkyl group having 1 to 6 carbon atoms
  • C 2 -C 6 alkenyl group refers to a straight or branched-chained alkenyl group having 2 to 6 carbon atoms
  • cycloalkyl group refers to a cycloalkyl group having 3 to 8 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • heterocycloalkyl group is 3 to 7 membered heterocyclic group containing the same or different 1 to 4 hetero atom(s) such as oxygen, nitrogen or sulfur atom(s), and examples may include piperidinyl, pyrrolidinyl, piperazinyl, tetrahydrofuryl, tetrahydropyranyl, morpholinyl, azetidinyl, and homopiperazinyl.
  • heteroaryl group is 5 to 7 membered monocyclic or polycyclic group thereof containing 2 to 8 carbon atoms and the same or different 1 to 4 hetero atom(s) such as oxygen, nitrogen or sulfur atom(s).
  • the examples include pyrrole, furyl, thienyl, imidazolyl, thiazolyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl, tetrazolyl, pyridinyl, pyrazolyl, pyridazinyl, and pyrimidinyl.
  • the “halogen atom” includes fluorine, chlorine, bromine and iodine.
  • substituted or unsubstituted C 1 -C 6 alkyl group examples include a straight or branched-chained, or substituted or unsubstituted alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, substituted or unsubstituted cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl; hydroxyl group; cyano group; alkoxy group such as methoxy
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,617,357, US 20020156064, and Molecular Pharmacology, 66:1679-1689, 2004, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 is NR a R b where R a and R b are independently H or C 1-6 alkyl, or represents a 5 to 7 member ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S;
  • R 2 is H, C 1-8 alkyl, C 1-3 alkyl-Ar, C 1-3 alkyl-C 3-6 cycloalkyl, C 2-8 alkenyl, C 2-4 alkenyl-Ar, or C 2-4 alkenyl-C 3-6 cycloalkyl, wherein Ar is substituted or unsubstituted phenyl;
  • R 3 is NO 2 , halo, CN, C(O)OR 7 , COR 1 , or NR a R b where R a and R b are independently H or C 1-6 alkyl;
  • R 4 is H, OC 1-6 alkyl, halo, C(O)NR a R b , C(O)OR 7 , C 1-8 alkyl, OCHF 2 , CH 2 OR 8 , OC 1-3 alkyl-Ar, or CH 2 NHC(O)CH 3 ;
  • R 5 is H, halo, or alkyl
  • R 6 is C 1-8 alkyl, OC 1-4 alkyl, or halo
  • R 7 is hydrogen or an ester or amide-forming group
  • R 8 is hydrogen or C 1-6 alkyl
  • a PDE7 inhibitor useful in the methods of the invention has the formula:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,852,720, EP 1 348 433, and WO 2003/082277, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 is a group selected from cycloalkyl, heterocycloalkyl, aryl and heteroaryl, those groups being optionally substituted by one or more groups, identical or different, selected independently of each other from halogen, trifluoromethyl, nitro, cyano, oxo, NR 4 R 5 , CO 2 R 4 , CONR 4 R 5 , OR 4 , S(O) n R 4 , S(O) n NR 4 R 5 , tetrazolyl and (C 1 -C 6 ) alkyl which is optionally substituted by 1 to 3 groups, identical or different, selected independently of each other from OR 4 , NR 4 , R 5 , and CO 2 R 4 ; wherein n is an integer from 0 to 2 inclusive, R 4 and R 5 are identical or different and independently of each other are a hydrogen atom or a group of formula X 1 —R a , wherein X 1 is a single bond or a (C 1 -C 6
  • R 2 is a group selected from (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, aryl, and cycloalkyl,
  • R 3 is a group selected from cycloalkyl, heterocycloalkyl, aryl and heteroaryl, these groups being optionally substituted by one or more groups, identical or different, selected independently of each other from halogen, nitro, cyano, trifluoromethyl, oxo, (C 1 -C 6 ) alkyl, OR 6 , NR 6 R 7 , COR 6 , CO 2 R 6 , CONHOH, CONR 6 R 7 , S(O) m R 6 , S(O) m NR 6 R 7 , NR 6 COR 7 , NR 6 SO 2 R 7 , N(SO 2 R 7 ) 2 , NR 6 CONR 7 R 8 , C( ⁇ NCN)NR 6 R 7 , NR 8 C( ⁇ NCN)NR 6 R 7 , and tetrazolyl optionally substituted with a (C 1 -C 4 ) alkyl, wherein m is an integer from 0 to 2 inclusive, R 6 and
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,753,340, US 20030191167, EP 1 348 701, and WO 2003/082839, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1a is a group selected from hydrogen, (C 1 -C 6 ) alkyl and aryl(C 1 -C 6 ) alkyl,
  • R 1b is a group selected from cycloalkyl, heterocycloalkyl, aryl and heteroaryl, those groups being optionally substituted by one or more groups, identical or different, selected independently of each other from halogen, trifluoromethyl, nitro, cyano, oxo, NR 4 R 5 , CO 2 R 4 , CONR 4 R 5 , OR 4 , S(O) n R 4 , S(O) n NR 4 R 5 , tetrazolyl, and (C 1 -C 6 ) alkyl which is optionally substituted by 1 to 3 groups, identical or different, selected independently of each other from OR 4 , NR 4 , R 5 , and CO 2 R 4 , wherein n is an integer from 0 to 2 inclusive, R 4 and R 5 are identical or different and independently of each other are a hydrogen atom or a group of formula X 1 —R a , wherein X 1 is a single bond or a (C 1 -
  • R 2 is a group selected from (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, aryl and cycloalkyl,
  • R 3 is a group selected from cycloalkyl, heterocycloalkyl, aryl and heteroaryl, these groups being optionally substituted by one or more groups, identical or different, selected independently of each other from halogen, nitro, cyano, trifluoromethyl, oxo, (C 1 -C 6 ) alkyl, OR 6 , NR 6 R 7 , COR E , CO 2 R 6 , CONHOH, CONR 6 R 7 , S(O) m R 6 , S(O) m NR 6 R 7 , NR 6 COR 7 , NR 6 SO 2 R 7 , N(SO 2 R 7 ) 2 , NR 6 CONR 7 R 8 , C( ⁇ N—CN)NR 6 R 7 , NR 8 C( ⁇ N—CN)NR 6 R 7 , and tetrazolyl optionally substituted with a (C 1 -C 4 ) alkyl, wherein m is an integer from 0 to 2 inclusive, R
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,849,638, US 20030119829, and WO 2002/088138, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-7 carbon atoms, fully saturated heterocycle of 2-6 carbon atoms and 1-2 heteroatoms selected from NH, S and O, aryl of 6-12 carbon atoms, that may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms or heteroaryl of 4-11 carbon atoms and 1, 2 heteroatoms selected from N
  • saturated or unsaturated ring may be substituted with 1-2 substituents selected from the group consisting of OH, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-7 carbon atoms, fully saturated heterocycle of 2-6 carbon atoms and 1-2 heteroatoms selected from NH, S, and O, halogen, haloalkyl of 1-2 carbon atoms and a number of halogen atoms up to the perhalo level, alkoxy of 1-6 carbon atoms, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, and R 9 -R 10 ; or
  • R 1 and R 2 combine to form, together with the nitrogen atom to which they are attached, an 8-10 membered bicyclic saturated ring;
  • R 3 is selected from the group consisting of NH, S, S( ⁇ O) 2 , and O;
  • R 4 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, C( ⁇ C), S( ⁇ O) 2 , and C( ⁇ O)O;
  • R 5 is selected from hydrogen, OH, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atom, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, aryl of 6-12 carbon atoms, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, which may be substituted
  • R 6 and R 7 are independently selected from hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, and alkynyl of 2-8 carbon atoms, or R 6 and R 7 combine together with the nitrogen atom to which they are attached to form a 5-7 membered, unsaturated ring which may contain 1-2 additional heteroatoms selected from N, S and O or to form a 5-7 membered, saturated ring which may contain 1-2 additional heteroatoms selected from NH, S, and O;
  • R 8 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, R 11 -R 12 , cycloalkyl of 3-7 carbon atoms, fully saturated heterocycle of 2-6 carbon atoms and 1-2 heteroatoms selected from NH, S, and O, aryl of 6-12 carbon atoms, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S
  • R 9 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, and alkynyl of 2-8 carbon atoms,
  • R 10 is selected from OH, aryl of 6-12 carbon atoms, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms
  • R 11 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, and alkynyl of 2-8 carbon atoms;
  • R 12 is selected from cycloalkyl of 3-7 carbon atoms, fully saturated heterocycle of 2-6 carbon atoms and 1-2 heteroatoms selected from NH, S, and O, aryl of 6-12 carbon atoms, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S and O, which may be substituted with alkyl of 1-6 carbon atom
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 2005222138 and WO 2003/064389, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 and R 2 are each independently, (1) hydrogen atom, or (2) C 1-8 alkyl, or
  • R 1 and R 2 may be taken together with the carbon atom to which they are attached to form Cycl,
  • R 1 and R 2 do not represent hydrogen atom at the same time
  • Z is (1) CR 3 R 4 , (2)O, (3) S, or (4) a bond
  • R 3 and R 4 are each independently, (1) hydrogen atom, (2) C 1-8 alkyl, (3) C 1-8 alkoxy, or (4) hydroxy, or
  • R 3 and R 4 may be taken together with the carbon atom to which they are attached to form Cycl or C(O);
  • R 5 and R 6 are each independently, (1) hydrogen atom, or (2) C 1-8 alkyl, or
  • R 5 and R 6 may be taken together with the carbon atom to which they are attached to form Cycl;
  • Cycl which is represented by R 1 and R 2 , R 3 and R 4 , R 5 and R 6 is, each independently, (1) C 3-10 cycloalkyl, or (2) 3-10 membered monocyclic hetero-ring comprising 1-2 of heteroatom selected from oxygen, nitrogen and sulfur, and Cycl may be substituted with R 10 ;
  • R 10 is (1) C 1-8 alkyl, (2) C 1-8 alkoxy, (3) hydroxy, (4) COOR 11 , (5) oxo, (6)SO 2 R 12 , or (7) COR 13 ;
  • R 11 is hydrogen atom, or C 1-8 alkyl
  • R 12 and R 13 are (1) C 1-8 alkyl, or (2) phenyl which may be substituted with C 1-8 alkyl;
  • R 7 and R 8 are each independently, (1) hydrogen atom, (2) C 1-8 alkyl, (3) C 1-8 alkoxy, (4) hydroxy, (5) cyano, (6) halogen atom, (7) COOR 14 , (8) CONR 15 R 16 , (9) Cyc2, (10) C 2-8 alkenyl, (11) C 2-8 alkynyl, (12) NR 51 R 52 , (13) nitro, (14) formyl, (15) C 2-8 acyl, (16) C 1-8 alkyl substituted with hydroxy, C 1-8 alkoxy, Cyc2, NR 51 R 52 , or NR 53 -Cyc2, (17) NR 54 COR 55 , (18) NR 56 SO 2 R 57 , (19) SO 2 NR 58 R 59 , (20) C 2-8 alkenyl substituted with COOR 14 , (21) CH ⁇ N—OH, (22) C 1-8 alkylene-NR 60 —(C 1-8 alkylene)-R 61 , (23) C 1-8 al
  • R 14 is hydrogen atom, or C 1-8 alkyl
  • R 15 and R 16 are each independently hydrogen atom or C 1-8 alkyl
  • R 51 and R 52 , R 58 and R 59 are each independently, hydrogen atom, or C 1-8 alkyl
  • R 53 , R 54 , R 56 , and R 60 are each independently, hydrogen atom, or C 1-8 alkyl;
  • R 55 is hydrogen atom, C 1-8 alkyl, or C 1-8 alkoxy;
  • R 57 is C 1-8 alkyl;
  • R 61 is NR 62 R 63 or hydroxy
  • R 62 and R 63 are each independently, hydrogen atom, or C 1-8 alkyl
  • R 65 is C 1-8 alkyl
  • R 137 is C 1-8 alkyl
  • Cyc2 wherein the group which attaches to carbonyl is carbon
  • R 7 , R 8 , and Cyc2 represented by ring are each independently, (1) C 3-15 mono-, bi- or tri-cyclic (fused or spiro)carboring, or (2) 3-15 membered mono-, bi- or tri-cyclic (fused or spiro)heteroring comprising 1-4 of heteroatom selected from oxygen, nitrogen and sulfur;
  • Cyc2 may be substituted with 1-5 of R 17 or R 17 ;
  • R 17 is (1) C 1-8 alkyl, (2) C 2-8 alkenyl, (3) C 2-8 alkynyl, (4) C 1-8 alkoxy, (5) C 1-8 alkylthio, (6) hydroxy, (7) halogen atom, (8) nitro, (9) oxo, (10) carboxy, (11) formyl, (12) cyano, (13) NR 18 R 19 , (14) phenyl, phenoxy or phenylthio, which may be substituted with 1-5 of R 20 , (15) C 1-8 alkyl, C 2-8 alkenyl, C 1-8 alkoxy or C 1-8 alkylthio, which may be substituted with 1-5 of R 21 (16) OCOR 22 , (17) CONR 23 R 24 , (18) SO 2 NR 25 R 26 (19) COOR 27 , (20) COCOOR 28 , (21) COR 29 , (22) COCOR 30 , (23) NR 32 COR 32 , (24) SO 2 R 33 , (25) NR
  • R 18 and R 19 , R 31 and R 34 are each independently, hydrogen atom, or C 1-8 alkyl;
  • R 20 and R 21 are C 1-8 alkyl, C 1-8 alkoxy, hydroxy, halogen atom, nitro, or COOR 36 ;
  • R 22 and R 64 are each independently C 1-8 alkyl
  • R 23 , R 24 , R 25 and R 26 are each independently hydrogen atom, C 1-8 alkyl, or phenyl;
  • R 27 , R 28 , R 29 , R 30 , R 32 , R 33 and R 35 are (1) C 1-8 alkyl, (2) C 2-8 alkenyl, (3) C 1-8 alkyl substituted with 1-5 of R 37 , (4) diphenylmethyl, (5) triphenylmethyl, (6) Cyc3, (7) C 1-8 alkyl or C 2-8 alkenyl substituted with Cyc3, (8) C 1-8 alkyl substituted with O-Cyc3, S-Cyc3 or SO 2 -Cyc3;
  • R 36 is hydrogen atom, or C 1-8 alkyl
  • R 37 is C 1-8 alkoxy, C 1-8 alkylthio, benzyloxy, halogen atom, nitro or COOR 38 ;
  • R 38 is hydrogen atom, C 1-8 alkyl or C 2-8 alkenyl
  • Cyc3 is (1) C 3-15 mono-, bi- or tri-cyclic (fused or spiro)carboring, or (2) 3-15 membered mono-, bi- or tri-cyclic (fused or spiro)heteroring comprising 1-4 of heteroatom selected from oxygen, nitrogen and sulfur;
  • Cyc3 may be substituted with 1-5 of R 39 ;
  • R 39 is (1) C 1-8 alkyl, (2) C 2-8 alkenyl, (3) C 2-8 alkynyl, (4) C 1-8 alkoxy, (5) C 1-8 alkylthio, (6) hydroxy, (7) halogen atom, (8) nitro, (9) oxo, (10) cyano, (11) benzyl, (12) benzyloxy, (13) C 1-8 alkyl, C 1-8 alkoxy or C 1-8 alkylthio substituted with 1-5 of R 40 , (14) phenyl, phenoxy, phenylthio, phenylsulfonyl or benzoyl which may be substituted with 1-5 of R 41 , (15) OCOR 42 , (16) SO 2 R 43 , (17) NR 44 COR 45 , (18) SO 2 NR 46 R 47 , (19) COOR 48 , or (20) NR 49 R 50 ;
  • R 40 is halogen atom
  • R 41 is C 1-8 alkyl, C 1-8 alkoxy, halogen atom, or nitro;
  • R 42 , R 43 and R 45 are C 1-8 alkyl
  • R 44 and R 48 are hydrogen atom or C 1-8 alkyl
  • R 46 and R 47 , R 49 and R 50 are each independently, hydrogen atom or C 1-8 alkyl
  • R 17′ is (1) SH, (2) NR 66 CHO, (3) CycS, (4) C 1-8 alkyl, C 2-8 alkenyl or C 2-8 alkynyl substituted with CycS, (5) CO—(NH-amino acid residue-CO)n-OH, (6) NR 67 CONR 68 R 69 , (7) CONR 70 NR 71 R 72 , (8) CONR 73 OR 74 , (9) CONR 75 COR 76 , (10) C(S)NR 77 R 78 , (11) CONR 79 C(S)COOR 80 , (12) NR 81 COCOOR 82 , (13) NR 83 COOR 84 , (14) CONR 85 C(S)R 86 , (15) OCOR 87 , (16) SOR 88 , (17) CONR 89 R 90 , (18) SO 2 NR 91 R 92 , (19) COOR 93 , (20) COCOOR 94 , (21) COR 95 , (2
  • n is an integer of 1 or 2;
  • R 66 , R 73 , R 75 , R 77 , R 79 , R 81 , R 83 , R 85 , R 97 , R 100 and R 102 are hydrogen atom, or C 1-8 alkyl;
  • R 67 and R 68 , R 70 and R 71 are each independently, hydrogen atom, or C 1-8 alkyl;
  • R 89 and R 91 are (1) hydrogen atom, (2) C 1-8 alkyl, (3) phenyl, or (4) C 1-8 alkyl substituted with cyano or C 1-8 alkoxy;
  • R 103 is Cyc6
  • R 69 , R 72 , R 74 , R 76 , R 78 , R 80 , R 82 , R 84 , R 86 , R 87 , R 88 , R 90 and R 92 are (1) hydrogen atom, (2) C 1-8 alkyl, (3) C 2-8 alkenyl, (4) C 2-8 alkynyl, (5) C 1-8 alkyl substituted with 1-5 of R 104 , (6) diphenylmethyl, (7) triphenylmethyl, (8) Cyc6, (9) C 1-8 alkyl or C 2-8 alkenyl substituted with Cyc6, or (10) C 1-8 alkyl substituted with O-Cyc6, S-Cyc6 or SO 2 -Cyc6;
  • R 104 is (1) C 1-8 alkoxy, (2) C 1-8 alkylthio, (3) benzyloxy, (4) halogen atom, (5) nitro, (6) COOR 105 , (7) cyano, (8) NR 106 R 107 , (9) N 108 COR 109 , (10) hydroxy, (11) SH, (12) SO 3 H, (13) S(O)OH, (14) OSO 3 H, (15) C 2-8 alkenyloxy, (16) C 2-8 alkynyloxy, (17) COR 110 , (18)SO 2 R 111 , or (19) C 1-8 alkoxy or C 1-8 alkylthio substituted with hydroxy;
  • R 105 is hydrogen atom, C 1-8 alkyl, or C 2-8 alkenyl
  • R 106 and R 107 are each independently, hydrogen atom, or C 1-8 alkyl
  • R 108 is hydrogen atom, or C 1-8 alkyl
  • R 109 and R 111 are C 1-8 alkyl
  • R 110 is C 1-8 alkyl, or halogen atom
  • R 93 , R 94 , R 95 , R 96 , R 98 , R 99 and R 101 are (1) C 2-8 alkynyl, (2) C 1-8 alkyl substituted with R 128 which may be substituted with 1-4 of R 29 , (3) Cyc8, (4) C 1-8 alkyl or C 2-8 alkenyl substituted with Cyc8, or (5) C 1-8 alkyl substituted with O-Cyc8, S-Cyc8 or SO 2 -Cyc8;
  • R 128 is (1) cyano, (2) NR 106 R 107 , (3) NR 108 COR 109 , (4) hydroxy, (5) SH, (6) SO 3 H, (7) S(O)OH, (8) OSO 3 H, (9) C 2-8 alkenyloxy, (10) C 2-8 alkynyloxy, (11) COR 110 , (12) SO 2 R 111 , or (13) C 1-8 alkoxy or C 1-8 alkylthio substituted with hydroxy;
  • R 129 has the same meaning as R 104 ;
  • Cyc5 and Cyc6 may be substituted with 1-5 of R 112 ;
  • R 112 is (1) C 1-8 alkyl, (2) C 2-8 alkenyl, (3) C 2-8 alkynyl, (4) C 1-8 alkoxy, (5) C 1-8 alkylthio, (6) hydroxy, (7) halogen atom, (8) nitro, (9) oxo, (10) cyano, (11) benzyl, (12) benzyloxy, (13) C 1-8 alkyl, C 1-8 alkoxy or C 1-8 alkylthio substituted with 1-5 of R 113 , (14) phenyl, phenoxy, phenylthio or benzoyl, which may be substituted with 1-5 of R 114, ( 15) COR 115 , (16) SO 2 R 116 , (17) NR 117 COR 118 , (18) SO 2 NR 119 R 120 , (19) COOR 121 , (20) NR 122 R 123 , (21) COR 124 , (22) CONR 125 R 126 , (23) SH, (24)
  • R 113 is halogen atom
  • R 114 is C 1-8 alkyl, C 1-8 alkoxy, halogen atom, or nitro;
  • R 115 , R 116 and R 118 are C 1-8 alkyl
  • R 117 , R 121 , R 124 and R 127 are hydrogen atom, or C 1-8 alkyl
  • R 119 and R 120 , R 122 and R 123 , R 125 and R 126 are each independently, hydrogen atom or C 1-8 alkyl;
  • Cyc7 may be substituted with 1-5 group selected from (1) C 1-8 alkyl, (2) C 1-8 alkoxy, (3) halogen atom, or (4) nitro;
  • Cyc8 may be substituted with R 130 , and it further may be substituted with 1-4 of R 131 ;
  • R 130 is (1) COR 124 , (2) CONR 125 R 126 , (3) SH, (4) C 1-8 alkyl substituted with hydroxy or NR 127 -benzoyl, or (5) Cyc7;
  • R 131 has the same meaning as R 112 ;
  • Cyc5, Cyc6, Cyc7 and Cyc8 are (1) C 3-15 mono-, bi- or tri-cyclic (fused or spiro) carboring, or (2) 3-15 membered mono-, bi- or tri-cyclic (fused or spiro) heteroring comprising 1-4 of heteroatom selected from 1-4 of oxygen, nitrogen or sulfur;
  • Cyc5 is not phenyl which may be substituted with 1-5 selected from C 1-8 alkyl, C 1-8 alkoxy, hydroxy, halogen atom, nitro, COOH, or COO(C 1-8 alkyl);
  • Cyc7 is not phenyl
  • Cyc4 is (1) C 5-7 monocyclic carboring, or (2) 5-7 membered monocyclic heteroring comprising 1-2 of heteroatom selected from oxygen, nitrogen and sulfur; (abbreviated as dashed line a hereafter;) and (abbreviated as dashed line b hereafter;) are (1) a bond, or (2) a double bond;
  • R 9 (1) absent or (2) is hydrogen atom
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2003/057149, expressly incorporated herein by reference in its entirety. In one embodiment. PDE7 inhibitors useful in the methods of the invention have the formula:
  • X is selected from halogen and NR 1 R 2 ,
  • Y is selected from NR 3 , S, and O, with the proviso that Y is not S when X is Cl,
  • R 1 and R 2 are independently selected from hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-7 carbon atoms, polycycloalkyl of 5-9 carbon atoms, heterocycloalkyl of 2-6 carbon atoms and 1-2 heteroatoms selected from NH, S, and O, aryl of 6-12 carbon atoms, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms, or heteroaryl of 4-11
  • R 3 is selected from hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, cycloalkyl of 3-7 carbon atoms, and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atom sup to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms, or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O,
  • R 4 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, C( ⁇ O), S( ⁇ O) 2 , and C( ⁇ O)O,
  • R 5 is selected from hydrogen, OH, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, alkynyl of 2-8 carbon atoms, alkoxy of 1-8 carbon atoms, thioxy of 1-8 carbon atoms, aryl of 6-12 carbon atoms, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms, or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected
  • R 6 and R 7 are independently selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, and alkynyl of 2-8 carbon atoms,
  • R 8 is selected from OH, aryl of 6-12 carbon atoms, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, haloalkyl of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, haloalkoxy of 1-6 carbon atoms and a number of halogen atoms up to the perhalo level, aryl of 6-12 carbon atoms or heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, and heteroaryl of 4-11 carbon atoms and 1-2 heteroatoms selected from N, S, and O, which may be substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkoxy of 1-6 carbon atoms
  • R 9 and R 10 are independently selected from hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, and alkynyl of 2-8 carbon atoms, or R 9 and R 10 combine together with the nitrogen atom to which they are attached to form a 5-7 membered, unsaturated ring which may contain 1-2 additional heteroatoms selected from N, S, and O, or to form a 5-7 membered, saturated ring which may contain 1-2 additional heteroatoms selected from NH, NR 11 , S, and O;
  • R 1 is selected from alkyl of 1-8 carbon atoms, alkenyl of 2-8 carbon atoms, and alkynyl of 2-8 carbon atoms, and pharmaceutically acceptable salts thereof.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 20030092721, U.S. Pat. No. 7,022,849, WO 2002/102315, and US 2006116516, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 is H or alkyl
  • R 2 is (a) heteroaryl or heterocyclo, either of which may be optionally substituted with one to three groups T1, T2, T3; or (b) aryl fused to a heteroaryl or heterocyclo ring wherein the combined ring system may be optionally substituted with one to three groups T1, T2, T3;
  • L is (a) OR 4 , C(O)R 4 , C(O)OR 4 , SR 4 , NR 3 R 4 , C(O)NR 3 R 4 , NR 3 SO 2 R 4b , halogen, nitro, or haloalkyl; or (b) alkyl, aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted with one to three groups T1a, T2a and/or T3a;
  • Y 1 , Y 2 and Y 3 are independently (a) hydrogen, halo, or —OR 4a ; or (b) alkyl, alkenyl, or alkynyl, any of which may be optionally substituted with one to three groups T1b, T2b and/or T3b;
  • R 3 and R 4 are independently H, alkyl, alkenyl, aryl, (aryl) alkyl, heteroaryl, (heteroaryl) alkyl, cycloalkyl, (cycloalkyl) alkyl, heterocyclo, or (heterocyclo) alkyl, any of which may be optionally substituted with one to three groups T1a, T2a and/or T3a; or
  • R 3 and R 4 together with the nitrogen atom to which they are attached may combine to form a 4- to 8-membered heterocyclo ring optionally substituted with one to three groups T1a, T2a and/or T3a;
  • R 4a is hydrogen, alkyl, alkenyl, aryl, heteroaryl, (aryl) alkyl, (heteroaryl) alkyl, heterocyclo, (heterocyclo) alkyl, cycloalkyl, or (cycloalkyl) alkyl, any of which may be optionally substituted with one to three groups T1b, T2b and/or T3b;
  • R 4b is alkyl, alkenyl, aryl, (aryl) alkyl, heteroaryl, (heteroaryl) alkyl, cycloalkyl, (cycloalkyl) alkyl, heterocyclo, or (heterocyclo) alkyl, any of which may be optionally substituted with one to three groups T1a, T2a and/or T3a;
  • Z is N or CH
  • T1-1b, T2-2b, and T3-3b are each independently;
  • T6 is (i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, or (heteroaryl)alkyl; (ii) a group (i) which is itself substituted by one or more of the same or different groups (i); or (iii) a group (i) or (ii) which is independently substituted by one or more of the following groups (2) to (13) of the definition of T1-1b, T2-2b and T3-3b;
  • T4 and 15 are each independently a single bond, T11S(O) t T12-, T11C(O)T12-, T11C(S)T12, T11OT12, T11ST12, T11OC(O)T12, T11C(O)OT12, T11C( ⁇ NT9a)T12, or T11C(O)C(O)T12;
  • T7, T8, T9, T9a and T10 are:
  • T7 and T8 may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T1-1b, T2-2b and T3-3b, or
  • T7 or T8, together with T9 may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T1-1b, T2-2b and T3-3b, or
  • T7 and T8 or T9 and T10 together with the nitrogen atom to which they are attached may combine to form a group N ⁇ CT13T14 where T13 and 114 are each independently H or a group provided in the definition of T6; and T11 and T12 are each independently a single bond, alkylene, alkenylene, or alkynylene.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,838,559, U.S. 20030100571, and WO 2002/102314, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • R 1 is H or alkyl
  • R 2 is (a) heteroaryl, or heterocyclo, either of which may be optionally substituted with one to three groups T1, T2, T3; (b) aryl substituted with one to three groups T1, T2, T3 provided that at least one of T1, T2, T3 is other than H; or (c) aryl fused to a heteroaryl or heterocyclo ring wherein the combined ring system may be optionally substituted with one to three groups T1, T2, T3;
  • Y is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclo, heteroaryl, (aryl)alkyl or (heteroaryl) alkyl any of which may be optionally substituted with one to three groups T1a, T2a, T3a;
  • J is (a) hydrogen, halo, or OR 4 , or (b) alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, or, cycloalkyl any of which may be optionally substituted with one to three groups T1b, T2b, T3b;
  • Z is (a) OR 4 , SR 4 , NR 3 R 4 , NR 3 SO 2 R 4a halogen, nitro, haloalkyl; or (b) alkyl, aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted with one to three groups T1c, T2c, T3c;
  • R 3 is H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl any of which may be optionally independently substituted where valance allows with one to three groups T1c, T2c, T3c;
  • R 4 is alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl any of which may be optionally independently substituted where valance allows with one to three groups T1d, T2d, or T3d; or
  • R 3 and R 4 together with the nitrogen atom to which they are attached may combine to form a 4 to 8 membered heterocyclo ring optionally substituted with one to three groups T1c, T2c, or T3c;
  • R 4a is hydrogen, alkyl, alkenyl, aryl, heteroaryl, (aryl)alkyl, (heteroaryl)alkyl, heterocyclo, (heterocyclo)alkyl, cycloalkyl or (cycloalkyl)alkyl any of which may be optionally substituted with one to three groups T1d, T2d or T3d;
  • T1-1d, T2-2d, and T3-3d are independently assigned to each other
  • T4 and T5 are each independently a single bond, T11-S(O) t -T12, T11-C(O)-T12, T11-C(S)-T12, T11-O-T12, -T11S-T12, -T11OC(O)-T12, -T11-C(O)O-T12, -T11C( ⁇ NT9a)-T12, or T11-C(O)—C(O)-T12;
  • T7, T8, T9, T9a and T10 are identical to T7, T8, T9, T9a and T10.
  • T7 and T8 may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T1-1d, T2-2d and T3-3d, or
  • T7 or T8, together with T9 may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T1-1d, T2-2d and T3-3d, or
  • T7 and T8 or T9 and T10 together with the nitrogen atom to which they are attached may combine to form a group N ⁇ CT13 T14 where
  • T13 and T14 are each independently H or a group provided in the definition of T6;
  • T11 and T12 are each independently a single bond, alkylene, alkenylene, or alkynylene.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 7,087,614, U.S. 20030162802, and WO 2002/102313, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1a is hydrogen or alkyl
  • R 2a is
  • W is S; X 1 is alkoxy; and X 2 is alkyl;
  • Z* is halogen, haloalkyl, oxazolyl, NR 3a R 4a , C(O)—N(H)-alkylene-COOH, or phenyl which is unsubstituted or substituted with heteroaryl, CO t H, or CO t T 6 ;
  • R 3a is hydrogen or alkyl
  • R 4a is alkyl, alkoxy, unsubstituted or substituted (heteroaryl) alkyl, unsubstituted or substituted heterocyclo, unsubstituted or substituted (heterocyclo) alkyl, or (aryl) alkyl wherein the aryl group is substituted with one or two groups T1 and/or T2 and/or further substituted with a group T3; or R 3a and R 4a together with the nitrogen atom to which they are attached combine to form an unsubstituted or substituted heterocyclo ring;
  • R 5a is an unsubstituted or substituted (heteroaryl) alkyl, or (aryl) alkyl wherein the aryl group is substituted with one or two groups T1 and/or T2 and/or further substituted with a group T3; or R 5a and R 6a together with the nitrogen atom to which they are attached combine to form an unsubstituted or substituted heterocyclo ring;
  • R 6a is hydrogen or alkyl;
  • J* is hydrogen or alkyl;
  • T1 and T2 are independently alkoxy, alkoxycarbonyl, heteroaryl, SO 3 H, or SO 2 R 8a where R 8a is alkyl, amino, alkylamino or dialkylamino; or T1 and T2 together with the aryl ring to which they are attached combine to form a bicyclic ring;
  • T3 is H, alkyl, halo, haloalkyl, or cyano;
  • t is 1 or 2; and
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 20030104974, WO 2002/088080, and WO 2002/088079, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • R 1 is H or alkyl
  • R 2 is optionally substituted heteroaryl, or 4-substituted aryl
  • R 3 is hydrogen or alkyl
  • R 4 is alkyl, optionally substituted (aryl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted heterocyclo, or optionally substituted (heterocyclo)alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached may combine to form an optionally substituted heterocyclo ring
  • R 5 is alkyl, optionally substituted (aryl)alkyl, or optionally substituted (heteroaryl)alkyl
  • R 6 is hydrogen or alkyl.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1a is H or alkyl; R 2a is optionally substituted heteroaryl; Z is halogen, alkyl, substituted alkyl, haloalkyl, or NR 3a R 4a ;
  • R 1a is hydrogen or alkyl;
  • R 4a is alkyl, optionally substituted (heteroaryl) alkyl, optionally substituted heterocyclo, optionally substituted (heterocyclo) alkyl, or (aryl) alkyl wherein the aryl group is substituted with one or two groups T1 and T2 and optionally further substituted with a group T3; or R 3a and R 4a together with the nitrogen atom to which they are attached may combine to form an optionally substituted heterocyclo ring;
  • R 5a is (aryl) alkyl wherein the aryl group is substituted with one or two groups T1 and T2 and optionally further substituted with a group T3;
  • R 6a is hydrogen or alkyl;
  • R 7a is
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1b is H or alkyl; R 2b is optionally substituted heteroaryl; R 3b is H or alkyl; R 4b is optionally substituted (aryl)alkyl; R 5b is H, alkyl, or C(O)(CH 2 ) v OYR 6b , where Y is a bond or C(O), R 6b is hydrogen or alkyl, and v is an integer from 0 to 2; J 1 and J 2 are independently optionally substituted C 1-13 alkylene, provided that J 1 and J 2 are not both greater than C 2 alkylene; X 4 and X 5 are optional substituents bonded to any available carbon atom in one or both of J 1 and J 2 , independently selected from hydrogen, OR 7 , NR 8 R 9 , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1c is H or alkyl
  • R 2c is optionally substituted heteroaryl
  • R 3c is H or alkyl
  • R 4c is optionally substituted (aryl)alkyl
  • X 4 and X 5 are optional substituents bonded to any available carbon atom in one or both of J 1 and J 2 , independently selected from hydrogen, OR 7 , NR 8 R 9 , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, or heteroaryl.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 20030092908 and WO 2002/087513, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 is hydrogen or alkyl
  • R 2 is (a) heteroaryl, or heterocyclo, either of which may be optionally substituted with one to three groups T1, T2, T3; (b) aryl substituted with one to three groups T1, T2, T3 provided that at least one of T1, T2, T3 is other than H; or (c) aryl fused to a heteroaryl or heterocyclo ring wherein the combined ring system may be optionally substituted with one to three groups T1, T2, T3;
  • Z is NR 3 R 4 , NR 3 SO 2 R 4a , OR 4 , SR 4 , haloalkyl, or halogen;
  • R 3 and R 4 are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl any of which may be optionally independently substituted where valance allows with one to three groups T1a, T2a, or T3a; or
  • R 3 and R 4 may be taken together with the nitrogen atom to which they are attached to form a heterocyclo or heteroaryl ring optionally independently substituted where valance allows with one to three groups T1a, T2a, or T3a;
  • R 4a is alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl any of which may be optionally independently substituted where valance allows with one to three groups T1a, T2a, or T3a;
  • R 3b and R 4b are independently H, alkyl, alkenyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo or (heterocyclo)alkyl;
  • R 6 is H, alkyl, alkenyl, NR 3b R 4b , heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, (NR 3b R 4b )alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T1b, T2b, or T3b;
  • R 6a is alkyl, alkenyl, NR 3b R 4b , heterocyclo, (heterocyclo)alkyl, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, (NR 3b R 4b )alkyl, heteroaryl, aryl or (aryl)alkyl, any of which may be optionally independently substituted where valance allows with one to three groups T1b, T2b, or T3b;
  • J 1 and J 2 are independently optionally substituted C 1-3 alkylene, provided that J 1 and J 2 are not both greater than C 2 alkylene;
  • T1-1b, T2-2b, and T3-3b are each independently
  • T6 is (i) alkyl, (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl) alkyl, heterocyclo, (heterocyclo)alkyl, heteroaryl, or (heteroaryl)alkyl; (ii) a group (i) which is itself substituted by one or more of the same or different groups (i); or (iii) a group (i) or (ii) which is independently substituted by one or more (preferably 1 to 3) of the following groups (2) to (13) of the definition of T1-1b, T2-2b, and T3-3b,
  • T4 and T5 are each independently (1) a single bond, (2) T1′-S(O) t -T12, (3) T11-C(O)-T12, (4) T11-C(S)-T12, (5)-T11-O-T12, (6) T11-S-T12, (7) T11-O—C(O)-T12, (8) T11-C(O)—O-T12, (9) T11-C( ⁇ NT9a)-T12, or (10) T11-C(O)—C(O)-T12,
  • (1) are each independently hydrogen or a group provided in the definition of T6, or
  • T7 and T8 may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T1-1b, T2-2b, and T3-3b, or
  • T7 or T8, together with T9 may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T1-1b, T2-2b, and T3-3b, or
  • T7 and T8 or T9 and T10 together with the nitrogen atom to which they are attached may combine to form a group N ⁇ CT13T14 where T13 and T14 are each independently H or a group provided in the definition of T6;
  • T11 and T12 are each independently a single bond, alkylene, alkenylene, or alkynylene.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 20040127707 and WO 2002/085906, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 is 1-2C-alkoxy or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,
  • R 2 is fluorine, bromine, or chlorine
  • R 3 and R 4 are both hydrogen or together form an additional bond
  • R 5 is R 6 , C m H 2m —R 7 , C n H 2n —C(O)R 8 , CH(R 9 ) 2 , C p H 2 p-Y-Aryll, R 12 or R 26 , wherein
  • R 6 1-8C-alkyl, 3-10C-cycloalkyl, 3-7C-cycloalkylmethyl, 3-7C-alkenyl, 3-7C-alkinyl, phenyl-3-4C-alkenyl, 7-10C-polycycloalkyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, quinazolinyl, quinoxalinyl, cinnolinyl, isoquinolinyl, quinolinyl, indanyl, indazolyl, benzoxazolyl, benzothiazolyl, oxazolyl, thiazolyl, N-methylpiperidyl, tetrahydropyranyl, 6-methyl-3-trifluoromethyl-pyridin-2-yl, 1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl, 3-thiophen-2-
  • R 61 is hydroxyl, 1-4C-alkyl, 1-4C-alkoxy, nitro, cyano, halogen, carboxyl, hydroxycarbonyl-1-4C-alkyl, 1-4C-alkoxycarbonyl, hydroxy-1-4C-alkyl, amino, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, aminocarbonyl, mono- or di-1-4C-alkylaminocarbon-yl, aminosulfonyl, mono- or di-1-4C-alkylaminosulfonyl, 4-methylphenylsulfonamido, imidazolyl; tetrazol-5-yl, 2-(1-4C-alkyl)tetrazol-5-yl or 2-benzyltetrazol-5-yl and
  • R 62 is 1-4C-alkyl, 1-4C-alkoxy, nitro, or halogen,
  • R 7 is hydroxyl, halogen, cyano, nitro, nitroxy(O—NO 2 ), carboxyl, carboxyphenyloxy, phenoxy, 1-4C-alkoxy, 3-7C-cydoalkoxy, 3-7C-cycloalkylmethoxy, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, 1-4C-alkylcarbonyl, 1-4C-alkoxycarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, amino, mono- or di-1-4C-alkylamino, or an unsubstituted or by R 71 and/or R 72 substituted piperidyl, piperazinyl, pyrrolidinyl or morpholinyl radical, wherein
  • R 71 is hydroxyl, 1-4C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxycarbonyl, and
  • R 72 is 1-4C-alkyl, carboxyl, aminocarbonyl or 1-4C-alkoxycarbonyl,
  • R 8 is an unsubstituted or by R 81 and/or R 82 substituted phenyl, naphthyl, phenanthrenyl or anthracenyl radical, wherein
  • R 81 is hydroxyl, halogen, cyano, 1-4C-alkyl, 1-4C-alkoxy, carboxyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonyloxy, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine, and
  • R 82 is hydroxyl, halogen, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,
  • R 9 is C q H 2q -phenyl
  • Y is a bond or O (oxygen)
  • Aryl 1 is an unsubstituted phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, quinazolinyl, quinoxalinyl, cinnolinyl, isoquinolyl, quinolyl, coumarinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, N-benzosuccinimidyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, furyl, thienyl, pyrrolyl, a 2-(1-4C-alkyl)-thiazol-4-yl radical, or a phenyl radical substituted by R 10 and/or R 11 , wherein
  • R 10 is hydroxyl, halogen, nitro, cyano, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, carboxyl, hydroxycarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyloxy, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, aminocarbonyl, mono- or di-1-4C-alkylamino-carbonyl, imidazolyl or tetrazolyl, and R 11 is hydroxyl, halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,
  • n is an integer from 1 to 4
  • p is an integer from 1 to 6
  • q is an integer from 0 to 2
  • R 12 is a radical of formula
  • R 13 is S(O) 2 —R 14 , S(O) 2 —(CH 2 ) r R 15 , (CH 2 ) s —S(O) 2 R 16 , C(O)R 17 , C(O)—(CH 2 ) r R 18 , (CH 2 ) s —C(O)—R 19 , Hetaryll, Aryl 2 or Aryl 3 -1-4C-alkyl, R 14 is 1-4C-alkyl, 5-dimethylaminonaphthalin-1-yl, N(R 20 )R 21 , phenyl or phenyl substituted by R 22 and/or R 23 , R 15 is N(R 20 )R 21 , R 16 is N(R 20 )R 21 ,
  • R 17 is 1-4C-alkyl, hydroxycarbonyl-1-4C-alkyl, phenyl, pyridyl, 4-ethyl-piperazin-2,3-dion-1-yl, 2-oxo-imidazolidin-1-yl or N(R 20 )R 21
  • R 18 is N(R 20 )R 21
  • R 19 is N(R 20 )R 21
  • R 20 and R 21 are independent from each other hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl or phenyl, or R 20 and R 21 together and with inclusion of the nitrogen atom to which they are bonded, form a 4-morpholinyl-ring, 1-pyrrolidinyl-ring, 1-piperidinyl-ring, 1-hexahydroazepino-ring or a 1-piperazinyl-ring
  • R 25 is pyrid-4-yl, pyrid4-ylmethy; 1-4C-alkyl-dimethylamino, dimethylaminocarbonylmethyl, N-methyl-piperidin-4-yl, 4-morpholino-ethyl or tetrahydrofuran-2-ylmethyl-
  • R 22 is halogen, nitro, cyano, carboxyl, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, amino, mono- or di-14C-alkylamino, aminocarbonyl 1-4C-alkylcarbonylamino or mono- or di-1-4C-alkylaminocarbon-yl
  • R 23 is halogen, amino, nitro, 1-4C-alkyl or 1-4C-alkoxy
  • R 24 is halogen
  • Hetaryl 1 is pyrimidin-2-yl, thieno-[2,3-d]pyrimidin-4-yl, 1-methyl-1H-pyrazolo-[3,4-d]pyrimidin-4-yl, thiazolyl, imidazolyl or furanyl
  • Aryl 2 is pyridyl, phenyl or phenyl substituted by R 22 and/or R 23
  • Aryl 3 is pyridyl, phenyl, phenyl substituted by R 22 and/or R 23 , 2-oxo-2H-chromen-7-yl or 4-(1,2,3-thiadiazol-4-yl)phenyl,
  • r is an integer from 1 to 4
  • s is an integer from 1 to 4
  • R 26 is a radical of formula
  • R 27 is C(O)R 28 , (CH 2 ) t —C(O)R 29 , (CH 2 ) u R 30 , Aryl 4 , Hetaryl 2 , phenylprop-1-en-3-yl or 1-methylpiperidin-4-yl, R 28 hydrogen, 1-4C-alkyl, OR 31 , furanyl, indolyl, phenyl, pyridyl, phenyl substituted by R 34 and/or R 35 or pyridyl substituted by R 36 and/or R 37 , R 29 is N(R 32 )R 33 , R 30 is N(R 32 )R 33 , tetrahydrofuranyl or pyridinyl, R 31 is 1-4C-alkyl, R 32 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl, R 33 is hydrogen, 1-4C-alkyl, 3-7C-cycloalky
  • R 32 and R 33 together and with inclusion of the nitrogen atom to which they are bonded, form a 4-morpholinyl-, 1-pyrrolidinyl-, 1-piperidinyl- or 1-hexahydroazepinyl-ring,
  • Aryl 4 is phenyl, pyridyl, pyrimidinyl, phenyl substituted by R 34 and/or R 35 , pyridyl substituted by R 36 and/or R 37 , R 34 is halogen, nitro, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy, R 35 is halogen or 1-4C-alkyl, R 36 is halogen, nitro, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy, R 37 is halogen or 1-4C-alkyl,
  • Hetaryl 2 is indol-4-yl, 2-methyl-quinolin-4-yl, 5-chloro-6-oxo-1-phenyl-1,6-dihydro-pyridazin-4-y-1,3-phenyl-1,2,4-thiadiazol-5-yl or 3-o-tolyl-1,2,4-thiadiazol-5-yl,
  • t is an integer from 1 to 4
  • u is an integer from 1 to 4
  • v is an integer from 1 to 2
  • X is —C(O)— or —S(O) 2 —, and the salts of these compounds.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,818,651, US 20040044212, and WO 2002/040450, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 denotes hydrogen
  • R 2 denotes fluorine, chlorine, bromine, cyano, trifluoromethyl or phenoxy
  • R 1 denotes hydrogen, fluorine, chlorine, bromine, trifluoromethyl or cyano
  • R 2 denotes hydrogen
  • R′ and R′′ both denote hydrogen or together represent a bond
  • Ar represents a phenyl radical of the formulae IIa, IIb, or IIc
  • R 3 denotes hydrogen, hydroxyl, nitro, amino, carboxyl, aminocarbonyl, 1-4C-alkoxy, trifluoromethoxy, 1-4C-alkoxycarbonyl or mono- or di-1-4C-alkylaminocarbonyl,
  • R 4 represents 1-4C-alkyl, naphthaleny, 5-dimethylaminonaphthalen-1-yl, phenylethen-2-yl, 3,5-dimethylisoxazol-4-yl, 5-chloro-3-methylbenzo[b]thiophen-2-yl, 6-chloro-imidazo[2,1b]-thiazol-5-yl, or represents a phenyl or thiophene radical which is unsubstituted or is substituted by one or more identical or different radicals selected from the group halogen, cyano, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy which is substituted entirely or mainly by fluorine, 1-4C-alkoxy, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonyl, phenylsulfonyl or isoxazolyl, or
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2002/040449, expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 denotes hydrogen and R 2 denotes fluorine, chlorine, bromine, cyano, trifluoromethyl or phenoxy, or
  • R 1 denotes hydrogen, fluorine, chlorine, bromine, trifluoromethyl or cyano and R 2 denotes hydrogen
  • R′ and R′′ both denote hydrogen or together represent a bond
  • R 3 denotes hydrogen, hydroxyl, nitro, amino, carboxyl, aminocarbonyl, 1-4C-alkoxy, trifluoromethoxy, 1-4C-alkoxycarbonyl or mono- or di-1-4C-alkylaminocarbonyl and R 4 denotes C(O)—X—R 5 , N(H)—C(O)—R 6 or N(H)—C(O)—N(H)—R 2 , wherein
  • X denotes 0 or N(H)
  • R 5 denotes hydrogen, 1-4C-alkyl, 3-7C-cycloalkylmethyl, 6,6-dimethylbicyclo[3,3,I]hept-2-yl, 3-7C-alkynyl, 1-4C-alkylcarbonyl-1-4C-alkyl, aminocarbonyl-1-4C-alkyl, furan-2-ylmethyl, 2-pyridin-2-yleth-1-yl, 2-pyridin-3-ylmethyl, N-methylpiperidin-3-yl, 1-benzylpiperidin-4-yl, morpholin-4-yl-eth-2-yl, morpholin-4-yl-eth-1-yl, 2-benzo[1,3]dioxol-4-yl-eth-1-yl, chroman-4-yl, 1-methoxycarbonyl-2-indol-3-yl-eth-1-yl, 1,3-bis-methoxycarbonylprop-1-yl, 1-methoxycarbonyl
  • R 6 denotes 2,4-dichlorophenoxymethyl, 2-tert-butoxycarbonylamino-eth-1-yl, 1-acetylpiperidin-4-yl, Ar1 or Ar2-CH ⁇ CH—,
  • Ar1 represents 3-chlorophenyl, 4-trifluoromethoxyphenyl, 3-phenoxyphenyl, indol5-yl, 2-methylpyridin-5-yl, quinolin-6-yl or 2-benzothiazol-6-yl
  • Ar2 represents furan-2-yl, furan-3-yl, thiophen-2-yl, indol-3-yl, 3-trifluoromethylphenyl, 3-methoxyphenyl or pyridin-3-yl
  • R 7 represents 1-4C-alkyl, 3-7C-alkenyl, 3-7C-cycloalkyl, 1-ethoxycarbonyl-2-phenyl-eth-1-yl, thiophen-2-yleth-1-yl or a phenyl radical which is unsubstituted or substituted by one or more radicals selected from the group halogen, cyano, 1-4C-alkyl, trifluoromethyl, 1-4C-alkylthio, 1-4C-alkoxy, 1-4C-alkoxy which is entirely or predominantly substituted by fluorine, 1-4C-alkylcarbonyl and phenoxy, or
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2001/098274, expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • W, X, Y and Z which may be the same or different, each represents a nitrogen atom or a C(R 5 ) group [wherein R 5 is a hydrogen or halogen atom or an alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxy, —NO 2 or —CN group] provided that two or more of W, X, Y, and Z are C(R 5 ) groups;
  • R 1 , R 2 and R 3 which may be the same or different, each is an atom or group -L 1 (Alk 1 ) r L 2 (R 6 ) s wherein L 1 and L 2 , which may be the same or different, is each a covalent bond or a linker atom or group, r is zero or the integer 1, Alk 1 is an aliphatic or heteroaliphatic chain, s is an integer 1, 2 or 3 and R6 is a hydrogen or halogen atom or a group selected from alkyl, —OR 7 [where R 7 is a hydrogen atom or an optionally substituted alkyl group], —SR 7 , NR 7 R 8 [where R 8 is as just defined for R 7 and may be the same or different], —NO 2 , CN, CO 2 R 7 , SO 3 H, S(O)R 7 , SO 2 R 7 , OCO 2 R 7 , CONR 7 R 8 , OCONR 7 R 8 , CSNR 7 R 8 —
  • R 4 represents an optionally substituted phenyl, 1- or 2-naphthyl, pyridyl, pyrimidinyl, pyridazinyl, or pyrazinyl group;
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2001/074786, expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 represents an aryl or heteroaryl group
  • A, B, P, and E which may be the same or different, each represents a nitrogen atom or a C(R 2 ) group [wherein R 2 is a hydrogen or halogen atom or an alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxy, —NO 2 or —CN group] provided that two or more of A, B, D, and E are C(R 2 ) groups;
  • X represents an oxygen or sulphur atom or a N(R 3 ) group wherein R 3 is a hydrogen atom or an alkyl group;
  • Q, R, S, and T which may be the same or different each represents a nitrogen atom or a group C(R 4 ) [wherein R 4 is an atom or group -L I (Alk 1 )rL 2 (R 5 )s wherein L 1 and L 2 , which may be the same or different, is each a covalent bond or a linker atom or group, r is zero or the integer 1, Alkyl is an aliphatic or heteroaliphatic chain, s is an integer 1, 2 or 3 and R 5 is a hydrogen or halogen atom or a group selected from alkyl, OR 6 [where R 6 is a hydrogen atom or an optionally substituted alkyl group], SR 6 , NR 6 R 7 [where R 7 is as just defined for R 6 and may be the same or different], NO 2 , CN, CO 2 R 6 , SO 3 H, S(O)R 6 , SO 2 R 6 , OCO 2 R 6 , CONR 6 R 7 , OCONR 6
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2000/068230, expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • X—Y—Z represents NR 4 —C ⁇ N or N ⁇ C—NR 4 ;
  • R 1 represents H, alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
  • R 2 represents OR 8 , NR 8 R 9 , SR 13 , alkyl or CF 3 ;
  • R 3 represents halogen, alkyl, CF 3 or OR 8 ;
  • R 4 which can be attached to either X or Z, is a residue selected from
  • attachment is through any position on the saturated ring, provided the attachment is not at a position adjacent to V, and the saturated ring may be substituted at any position with one or more R 6 ;
  • A, B, D, and E are the same or different and each represents Cl n R 5 , N or N—O;
  • V represents O, S, NR 7 or C(L 1 m R 14 )(L 2 n R 14 );
  • Q and W are the same or different and each represents CL n R 5 or N;
  • T represents O, S or NR 7 ;
  • L 1 and L 2 are the same or different and each represents C(R 15 ) 2 ;
  • n and n are the same or different and each represents 0, 1, 2, 3, 4 or 5;
  • the R 5 s are the same or different and each represents H, halogen, alkyl, cycloalkyl, OR 8 , NR 8 R 9 , CO 2 R 10 , CONR 11 R 12 , CONHOH, SO 2 NR 11 R 12 , SON 11 R 12 , COR 13 , SO 2 R 13 , SOR 13 , SR 13 , CF 3 , NO 2 or CN;
  • R 6 represents H, alkyl, cycloalkyl, OR 8 , NR 8 R 9 , CO 2 R 10 , CONR 11 R 12 , SO 2 NR 11 R 12 , SON 11 R 12 , COR 13 , SO 2 R 13 , SOR 13 , SR 13 , CF 3 , CN or ⁇ O;
  • R 7 represents H or alkyl
  • R 8 represents H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;
  • R 9 represents R 8 or alkylcarbonyl, alkoxycarbonyl, alkylsulphonyl, cycloalkylcarbonyl, cycloalkoxycarbonyl, cycloalkylsulphonyl, cycloalkylalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkylsulphonyl, arylcarbonyl, arylsulphonyl, heteroarylcarbonyl, heteroarylsulphonyl, heterocyclocarbonyl, heterocyclosulphonyl, arylalkylcarbonyl, arylalkoxycarbonyl, arylalkylsulphonyl, heteroarylalkylcarbonyl, heteroarylalkoxycarbonyl, heteroarylalkylsulphonyl, heteroarylalkylcarbonyl, heteroarylalkoxycarbonyl, heteroarylsulphonyl, heterocycloalkylcarbonyl, hetero
  • NR 8 R 9 represents a heterocyclic ring such as morpholine
  • R 10 represents H, alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
  • R 11 and R 12 are the same or different and are each R 8 , or NR 11 R 12 represents a heterocyclic ring such as morpholine;
  • R 13 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;
  • the R 14 s are the same or different and are each selected from H alkyl, cycloalkyl, OR 8 , NR 8 R 9 , CO 2 R 10 , CONR 11 R 12 , CONHOH, SO 2 NR 11 R 12 , SON 11 R 12 , COR 13 , SO 2 R 13 , SOR 13 , SR 13 , CF 3 , NO 2 and CN, provided that when both m and n represent 0, if one R 14 is OR 8 , NR 8 R 9 or SR 13 , the other is not OR 8 , NR 8 R 9 or SR 13 ; and
  • R 15 represents H, alkyl or F
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 20040106631, EP 1 400 244, and WO 2004/026818, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • n 1, 2 or 3;
  • R 1 is methyl, chloro, bromo or fluoro;
  • R 2 is -Q 1 -Q 2 -Q 3 -Q 4 or (C 1 -C 6 ) alkyl, said (C 1 -C 6 ) alkyl is substituted with one to three OR 4 , COOR 4 , NR 4 R 5 , NRC( ⁇ O)R 4 , C( ⁇ O)NR 4 R 5 or SO 2 NR 4 R 5 ;
  • R 4 is (C 1 -C 6 ) alkyl substituted with one to three F, CN, S( ⁇ O)R 6 , SO 3 H, SO 2 R 6 , SR 7 , C( ⁇ O)—NH—SO 2 —CH 3 , C( ⁇ O)R 7 , NR′C( ⁇ O)R 7 , NR′SO 2 R 6 , C( ⁇ O)NR 7 R 8 , O—C( ⁇ O)NR 7 R 8 or SO 2 NR 7 R 8 ;
  • R 5 is H or (C 1 -C 6 ) alkyl optionally substituted with one to three F, CN, S( ⁇ O)R 6 , SO 3 H, SO 2 R 6 , SR 7 , C( ⁇ O)—NH—SO 2 —CH 3 , C( ⁇ O)R 7 , NR′C( ⁇ O)R 7 , NR′SO 2 R 6 , C( ⁇ O)NR 7 R 8 , O—C( ⁇ O)NR 7 R 8 or SO 2 NR 7 R 8 ; or
  • OR 4a optionally substituted with one or two OR 4a , COOR 4a , C( ⁇ O)—R 4a , NR 4a R 5a , NRC( ⁇ O)R 4a , C( ⁇ O)NR 4 R 5a or SO 2 NR 4a R 5a ;
  • R 9 is H, CN, OH, OCH 3 , SO 2 CH 3 , SO 2 NH 2 or (C 1 -C 6 ) alkyl; and R 3 is (C 1 -C 6 ) alkyl optionally substituted with one to three F, CN, S( ⁇ O)R 6 , SO 3 H, SO 2 R 6 , C( ⁇ O)—NH—SO 2 —CH 3 , OR 7 , SR 7 , COOR 7 , C( ⁇ O)R 7 , O—C( ⁇ O)NR 7 R 8 , NR 7 R 8 , NR′C( ⁇ O)R 7 , NR′SO 2 R 6 , C( ⁇ O)NR 7 R 8 or SO 2 NR 7 R 8 ;
  • R 4a and R ya are the same or different and are H or (C 1 -C 6 ) alkyl optionally substituted with one to three F, CN, S( ⁇ O)R 6 , SO 3 H, SO 2 R 6 , C( ⁇ O)—NH—SO 2 —CH 3 , OR 7 , SR 7 , COOR 7 , C( ⁇ O)R 7 , O—C( ⁇ O)NR 7 R 8 , NR 7 R 8 , NR′C( ⁇ O)R 7 , NR′SO 2 R 6 , C( ⁇ O)NR 7 R 8 or SO 2 NR 7 R 8 ;
  • Q 1 is a single bond or (C 1 -C 6 ) alkylene
  • Q 2 is a saturated 4- to 6-membered heterocyclyl comprising one or two O or N
  • Q 3 is (C 1 -C 6 ) alkylene
  • Q 4 is a 4 to 8-membered, aromatic or non aromatic, heterocyclyl comprising 1 to 4 O, S, S( ⁇ O), SO 2 , or N, said heterocyclyl being optionally substituted with one to three OR, NRR′, —CN or (C 1 -C 6 ) alkyl;
  • R is H or (C 1 -C 6 ) alkyl
  • R 6 is (C 1 -C 6 ) alkyl optionally substituted with one or two OR′;
  • R 7 and R 8 are the same or different and are H or (C 1 -C 6 ) alkyl optionally substituted with one or two OR′;
  • R 9 is H, CN, OH, OCH 3 , SO 2 CH 3 , SO 2 NH 2 or (C 1 -C 6 ) alkyl;
  • R′ is H or (C 1 -C 6 ) alkyl
  • R′′ is H or (C 1 -C 6 ) alkyl
  • the atom of Q 2 bound to Q 1 is a carbon atom; and (2) the atom of Q 4 bound to Q 3 is a carbon atom;
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,936,609 and US 20040249148, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 represents (C 6 -C 10 )-aryl, which is optionally identically or differently substituted by radicals selected from the group consisting of halogen, formyl, carbamoyl, cyano, hydroxyl, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 6 )-alkyl or (C 1 -C 6 )-alkoxy, and optionally by a radical of the formula SO 2 NR 5 R 6 , wherein R 5 and R 6 independently of one another denote hydrogen or (C 1 -C 6 )-alkyl, or NR 5 R 6 denotes 4- to 8-membered heterocyclyl, bonded via a nitrogen atom, optionally identically or differently substituted by radicals selected from the group consisting of oxo, halogen, (C 1 -C 6 )-alkyl and (C 1 -C 6 )-acyl,
  • R 2 represents a saturated or partially unsaturated hydrocarbon radical having 1 to 10 carbon atoms
  • R 3 represents methyl or ethyl
  • A represents O, S, or NR S , wherein R 7 denotes hydrogen or (C 1 -C 6 )-alkyl optionally substituted by (C 1 -C 3 )-alkoxy,
  • E represents a bond or (C 1 -C 3 )-alkanediyl
  • R 4 represents (C 6 -C 10 )-aryl or 5- to 10-membered heteroaryl, where aryl and heteroaryl are optionally identically or differently substituted by radicals selected from the group consisting of halogen, formyl, carboxyl, carbamoyl, —SO 3 H, aminosulphonyl, cyano, hydroxyl, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, 1,3-dioxa-propane-1,3-diyl, (C 1 -C 6 )-alkylthio, (C 1 -C 6 )-alkylsulphinyl and (C 1 -C 6 )-alkyl-sulphonyl, —NR 8 R 9 end optionally methyl-substituted, 5- to 6-membered heteroaryl or phenyl,
  • R 8 and R 9 independently of one another denote hydrogen, (C 1 -C 6 )-alkyl or (C 1 -C 6 )-acyl, or salt thereof.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2006/092692, expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formulas:
  • n is an integer of from 1 to 4, and where there are stereocenters, each center may be independently R or S.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in US 2006229306 and WO 2004/065391, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R 1 and R 2 form, together with the nitrogen atom to which they are attached, a 3- to 8-membered ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which ring is saturated or unsaturated and optionally substituted by one or more substituents selected from halogen atoms, alkyl, hydroxy, alkoxy, acyl, hydroxycarbonyl, alkoxycarbonyl, alkylenedioxy, amino, mono- and di-alkylamino, mono- and di-alkylaminoacyl, nitro, cyano and trifluoromethyl groups;
  • R 3 is a group of formula (CH 2 ) n-G′ wherein n is an integer from 0 to 4 and G represents a monocyclic or bicyclic aryl or heteroaryl group comprising from zero to four heteroatoms which group is optionally substituted by one or more substituents selected from:
  • alkyl and alkylene groups wherein each alkyl and alkylene group is independently optionally substituted by one or more substituents selected from halogen atoms;
  • R 4 represents a hydrogen atom, an alkyl or an aryl group.
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2008/130619, expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • X is SO, or SO 2 ,
  • R1 is H, or alkyl
  • R2 is alkyl, or halogen.
  • R1 is Me. In other specific embodiments R1 is F. In certain embodiments R2 is t-Bu. In specific embodiments, R1 is methyl. In more specific embodiments, the compounds are selected from:
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R1 is alkyl
  • R2 is aryl or heteroaryl
  • R3 is alkyl, aryl, cycloakyl, or alkylaryl.
  • R1 is methyl.
  • R2 is furanyl or thiophenyl.
  • R2 is substituted phenyl or benzyl.
  • R3 is iso-butyl.
  • the compounds are selected from:
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R1 is nitrile, or alkylcarboxylate
  • R2 is alkyl, aryl, or heteroaryl.
  • R1 is nitrile or methylcarboxylate.
  • R2 is a five membered heteroaryl.
  • R2 is furanyl, or thienyl.
  • R2 is a six membered aryl.
  • R2 is substituted phenyl.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R1 is alkyl, alkenyl, or alkylcarboxylic acid
  • R2 is halogen
  • R1 is butyl. In other embodiments R1 is terminal alkenyl. In more specific embodiments R1 is allyl, or vinyl. In other embodiments, R1 is C 1-4 alkyl. In specific embodiments R1 is methylcarboxylic acid. In certain embodiments R2 is Cl, or Br. In more specific embodiments, the compounds are selected from:
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R1 is CO, or alkylalcohol
  • R2 is alkyl
  • R3 is alkoxy
  • the C4 and C9 stereocenters are independently (R) or (S).
  • R1 is carbonyl, or 2-methylpropan-1-ol.
  • R2 is methyl.
  • R3 is methoxy.
  • the compounds are selected from:
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R1 is hydrogen, hydroxyl, carbonyl, or alkylalcohol
  • R2 and R3 are independently selected from hydrogen, alkyl, alkylcarboxylate, or carboxylic acid,
  • R4 is hydrogen, or alkyl
  • R5 is hydrogen, alkyl, hydroxyl, or acetate
  • R6 is hydrogen, or alkoxy, and the C4 and C9 stereocenters are independently (R) or (S).
  • R1 is 2-methylpropan-1-ol.
  • R2 is methyl.
  • R2 is methylcarboxylate.
  • R2 and R3 are both methyl.
  • R2 is methyl, and R3 is methylcarboxylate.
  • R4 is iso-propyl.
  • R5 is methyl.
  • R6 is methoxy.
  • the compounds are selected from:
  • alkyl alkenyl and the prefix “alk-” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms.
  • Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, adamantly, norbornane, and norbornee. This is also true of groups that include the prefix “alkyl-”, such as alkylcarboxylic acid, alkyl alcohol, alkylcarboxylate, alkylaryl, and the like.
  • alkylcarboxylic acid groups are methylcarboxylic acid, ethylcarboxylic acid, and the like.
  • suitable alkylalcohols are methylalcohol, ethylalcohol, isopropylalcohol, 2-methylpropan-1-ol, and the like.
  • suitable alkylcarboxylates are methylcarboxylate, ethylcarboxylate, and the like.
  • suitable alkyl aryl groups are benzyl, phenylpropyl, and the like.
  • aryl as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N).
  • Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, thiazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
  • the aryl, and heteroaryl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroaryl
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in WO 2008/142550, expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • n 0, 1, 2 or 3
  • X is O, S or N—CN
  • R 1 is halogen or CN
  • A is a single bond, CH 2 , O or S,
  • B is a single bond, CH 2 or OCH 2 , each R 2 is independently halogen, (C 1-6 )alkyl (optionally substituted by 1 to 3 fluorine atoms), OH, (C 1-6 )alkylthio or CN,
  • R 3 is selected from the following groups (i) to (x):
  • R is H or (C 1-6 )alkyl (optionally substituted by 1 to 3 fluorine atoms), R′ is (C 1-6 )alkyl (optionally substituted by 1 to 3 fluorine atoms), or a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof.
  • alkyl denotes a monovalent, straight or branched, saturated hydrocarbon chain containing 1 to 6 carbon atoms
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, neopentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-ethylbutyl and 2,2-dimethylbutyl.
  • Preferred alkyl groups are particularly methyl and ethyl, especially methyl.
  • alkyl groups may be substituted by 1 to 3 fluorine atoms.
  • the substitution may be at any position on the alkyl chain.
  • fluorinated alkyl groups have 1 to 4 carbon atoms, more preferably 1 or 2 carbon atoms.
  • Mono-, di- and trifluoromethyl groups especially trifluoromethyl
  • mono-, di- and trifluoroethyl groups especially 2,2,2-trifluoroethyl
  • alkoxy denotes “alkyl-O—”, wherein “alkyl” is as defined above, either in its broadest aspect or a preferred aspect.
  • Preferred alkoxy groups are groups, particularly methoxy and ethoxy.
  • alkylthio denotes “alkyl-S-”, wherein “alkyl” is as defined above, either in its broadest aspect or a preferred aspect.
  • Preferred alkylthio groups are (C 1-4 )alkylthio groups, particularly methylthio and ethylthio.
  • halogen denotes fluoro, chloro, bromo or iodo. Preferred halogen groups are fluoro and chloro.
  • m is 0 or 1, more preferably 1.
  • n is 0 or 1, more preferably 0.
  • X is O or N—CN, more preferably O.
  • R 1 is F or Cl, more preferably Cl.
  • A is a single bond or O, more preferably O.
  • the oxygen atom is bonded to the benzene ring and the methylene group to the group R 3 .
  • B is a single bond.
  • R 2 is F or Cl, more preferably F.
  • R 3 is a group (i), (ii), (iii), (iv), (v) or (vi), more preferably a group (i) or (ii), and especially a group (ii).
  • the group —B—R 3 is present at the 2-position of the phenyl ring (the position of the group A being the 1-position). In other embodiments, the group —B—R 3 is present at the 3-position. In further embodiments, the group —B—R 3 is present at the 4-position.
  • PDE7 inhibitors useful in the methods of the invention include those in which each variable in the above formula is selected from the suitable and/or preferred groups for each variable. Even more preferred PDE7 inhibitors useful in the methods of the invention include those where each variable in the above formula is selected from the more preferred or most preferred groups for each variable.
  • PDE7 inhibitors are useful in the methods of the invention:
  • PDE7 inhibitors are useful in the methods of the invention:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 7,498,334, US 2005/0059686 and WO 2003/055882, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • X is phenyl or Het, each of which is unsubstituted or monosubstituted or polysubstituted by R1 and/or R2,
  • R1 and R2 are each, independently of one another, A, OH, OA, SA, SOA, SO2A, SO2NH2, SO2NHA, SO2AA′, CN, NO2, NH2, NHA, NAA′, NHCOA, NHCOOA, COOH, COOA, CONH2, CONHA, CONAA′ or Ha1,
  • R′ and R2 together are alternatively —OCH2O— or —OCH2CH2O—
  • R3 is A, OH, OA, SA, SOA, SO2A, SO2NH2, SO2NHA, SO2AA′, CN, NO2, NH2, NHA, NHB, NAA′, NHCOA, NHCOOA, NHCOB, NHCOOB, COOH, COOA, COOB, CONH2, CONHA, CONHB, CONAA′ or Ha
  • a and A′ together are alternatively alkylene having from 3 to 7 carbon atoms, in which one or two CH2 groups may be replaced by CHR7, CHR7R8, O, S, SO, SO2, NH, NR7, NHCO, NR7CO, NHCOO or NR7COO.
  • B is phenyl or Het, each of which is unsubstituted or monosubstituted or polysubstituted by R1 and/or R2, Het is an aromatic 5- or 6-membered heterocyclic ring having 1-3 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A′′, Ha1 or CF3, R7 and R8 are each, independently of one another, branched or unbranched alkyl or alkenyl having up to 5 carbon atoms, which may be substituted by from 1 to 5 F and/or Cl atoms and/or in which one or more CH2 groups may be replaced by O, S, SO, SO2 or NH, A′′ is alkyl having from 1 to 6 carbon atoms, and Ha1 is F, Cl, Br or I, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  • PDE7 inhibitors useful in the methods of the invention include compounds of the above formula in which R5 is OH may also be in the form of their tautomers of the formula:
  • PDE7 inhibitors useful in methods of the invention include the optically active forms (stereo-isomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds.
  • the term solvates of the compounds is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, monohydrates, dihydrates or alcoholates.
  • the term pharmaceutically usable derivatives is taken to mean, for example, the salts of the above compounds and so-called prodrug compounds.
  • prodrug derivatives is taken to mean, for example, the above compounds which have been modified, for example, with alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism and thus release the active compounds.
  • biodegradable polymer derivatives of the above compounds as described, for example, in Int. J. Pharm. 115, 61-67 (1995).
  • a and A′ are preferably alkyl, furthermore preferably alkyl which is substituted by from 1 to 5 fluorine and/or chlorine atoms, furthermore preferably alkenyl.
  • alkyl is preferably unbranched and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, preferably 1, 2, 3, 4, 5 or 6 carbon atoms, and is preferably methyl, ethyl, trifluoromethyl, pentafluoroethyl or propyl, furthermore preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl or n-hexyl. Particular preference is given to methyl, ethyl, trifluoromethyl, propyl, isopropyl, butyl, n-pentyl, n-hexyl or n-decyl.
  • A′′ is preferably alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, for example methyl, ethyl or propyl, furthermore preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl or n-hexyl. Particular preference is given to methyl, ethyl, propyl, isopropyl or butyl.
  • Cycloalkyl preferably has 3-7 carbon atoms and is preferably cyclopropyl or cyclobutyl, furthermore preferably cyclopentyl or cyclohexyl, furthermore also cycloheptyl; particular preference is given to cyclopentyl.
  • Alkenyl is preferably vinyl, allyl, 2- or 3-butenyl, isobutenyl or sec-butenyl; preference is furthermore given to 4-pentenyl, isopentenyl or 5-hexenyl.
  • Alkylene is preferably unbranched and is preferably methylene or ethylene, furthermore preferably propylene or butylene.
  • Ha1 is preferably F, Cl or Br, furthermore also I.
  • the radicals R1 and R2 may be identical or different and are preferably in the 2- or 4-position of the phenyl ring. They are, for example, independently of one another, A or Ha1, or together are methylenedioxy.
  • R1 is particularly preferably fluorine, chlorine, methyl, ethyl or propyl.
  • R2 is particularly preferably fluorine, chlorine, methyl, ethyl or propyl.
  • X is preferably a phenyl radical which is monosubstituted by R1 or is unsubstituted Het.
  • X is particularly preferably 2-chlorophenyl, 2-fluorophenyl, 4-methyl-phenyl, 3-chlorophenyl or 4-chlorophenyl.
  • Het is preferably, for example, unsubstituted 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, or 1,2,3-thia-diazol-4- or -5-yl.
  • R3 is preferably, for example, COOA′′ or COOH.
  • R4 is preferably, for example, unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which may be substituted by 1-5 F or Cl atoms, preferably methyl, ethyl, trifluoromethyl, pentafluoroethyl or propyl, furthermore preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl or n-hexyl. Particular preference is given to methyl, ethyl, trifluoromethyl, propyl, isopropyl, butyl, n-pentyl, n-hexyl or n-decyl.
  • R5 is preferably Cl or OH.
  • R6 is preferably H.
  • At least one of the said radicals has one of the preferred meanings indicated above.
  • PDE7 inhibitors useful in the methods of the invention include the following compounds, wherein X is a phenyl radical which is monosubstituted by R1, or is unsubstituted Het; R1 is A or Ha1; R3 is COOA′′ or COOH; R4 is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which may be substituted by 1-5 F or Cl atoms; R5 is Cl or OH; and R6 is H;
  • PDE7 inhibitors useful in the methods of the invention include the following compounds, wherein X is a phenyl radical which is monosubstituted by R1, or is unsubstituted Het, R1 is A or Ha1, R3 is COOA′′ or COOH, R4 is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which may be substituted by 1-5 F or Cl atoms, R5 is Cl or OH, R6 is H, Het is furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl, A and A′′ are each, independently of one another, unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which may be substituted by 1-5 F or Cl atoms, Ha1 is F, Cl or Br, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  • PDE7 inhibitors useful in the methods of the invention include:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,884,800 and WO 01/36425, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R1 and R2 independently of one another, each denote A1, OA1, SA1 or Ha1,
  • a 1 denotes H, A, alkenyl, cycloalkyl or alkylenecycloalkyl,
  • Ha1 denotes F, Cl, Br or I, and
  • x denotes O, S, SO or SO2, and their physiologically acceptable salts and/or solvates.
  • A denotes alkyl having 1-10 carbon atoms and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms and preferably denotes methyl, ethyl or propyl, furthermore preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl or hexyl.
  • 1-7H atoms may also be replaced by F and/or Cl.
  • A therefore also denotes, for example, trifluoromethyl or pentafluoroethyl.
  • Cycloalkyl has 3-9 carbon atoms and preferably denotes, for example, cyclopentyl or cyclohexyl.
  • Alkenyl has 2-10 carbon atoms, is linear or branched and preferably denotes vinyl, propenyl or butenyl.
  • Alkylenecycloalkyl has 4-10 carbon atoms and denotes, for example, methylenecyclopentyl, ethylenecyclopentyl, methylenecyclohexyl or ethylenecyclohexyl.
  • R1 and R2 preferably denote, in each case independently of one another, H, fluorine, chlorine, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, methylthio, cyclopentyl or cyclohexyl.
  • PDE7 inhibitors useful in the methods of the invention include the following compounds, wherein
  • X is S
  • X is S, R1 is H;
  • X is S, R1 is F or Cl;
  • X is S, R2 is H;
  • X is S, R1 is F or Cl;
  • X is S, R1 is H, R2 is F or Cl;
  • X is S, R1 is F or Cl, R2 is H;
  • X is S, R1 and R2, independently of one another, each denote A1 or Ha1, A1 is H or A, A is alkyl having 1, 2, 3 or 4 carbon atoms, Ha1 is F or Cl;
  • PDE7 inhibitors useful in the methods of the invention include the following compounds:
  • PDE7 inhibitors useful in the methods of the invention are selected from those compounds generally or specifically disclosed in U.S. Pat. No. 6,531,498 and WO 01/32175, each expressly incorporated herein by reference in its entirety.
  • PDE7 inhibitors useful in the methods of the invention have the formula:
  • R1, R2, R3, R4 are each, independently of one another, Ha1, OA1, SA1, A, H, COOA1, CN or CONA1A2,
  • R5 is COOA 1, CN or CONA1A2,
  • A1, A2 are each, independently of one another, H, A, alkenyl, cycloalkyl or alkylenecycloalkyl,
  • A is alkyl having 1 to 10 C atoms
  • Ha1 is F, Cl, Br or I
  • A is alkyl having 1-10 C atoms and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms and is preferably methyl, ethyl or propyl, also preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but is also n-pentyl, neopentyl, isopentyl or hexyl. It is also possible for 1-7H atoms in the radicals to be replaced by F and/or Cl. A is therefore also, for example, trifluoromethyl or pentafluoroethyl.
  • Cycloalkyl has 3-9 C atoms and is preferably, for example, cyclopentyl or cyclohexyl.
  • Alkenyl has 2-10 C atoms, is linear or branched and is preferably vinyl, propenyl or butenyl.
  • Alkylenecycloalkyl has 4-10 C atoms and is, for example methylenecyclopentyl, ethylenecyclopentyl, methylenecyclohexyl or ethylenecyclohexyl.
  • PDE7 inhibitors useful in the methods of the invention include the compounds wherein
  • R1 is H
  • R1 and R2 are H
  • R1 is H and R2 is F or Cl;
  • R1, R2 are each, independently of one another, H or Ha1;
  • R1, R2 are each, independently of one another, H or Ha1, A1, A2 are each, independently of one another, H or A;
  • A1, A2 are each, independently of one another, H or A;
  • R1, R2 are each, independently of one another, H or Ha1, A1, A2 are each, independently of one another, H or A, A is alkyl having 1, 2, 3 or 4 C atoms, Ha1 is F or Cl.
  • PDE7 inhibitors useful in the methods of the invention include the compounds:

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
US13/290,868 2010-11-08 2011-11-07 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors Abandoned US20120115849A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/290,868 US20120115849A1 (en) 2010-11-08 2011-11-07 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US14/960,750 US20160158247A1 (en) 2010-11-08 2015-12-07 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
US15/871,768 US11207275B2 (en) 2010-11-08 2018-01-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US16/191,119 US11464785B2 (en) 2010-11-08 2018-11-14 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US17/530,011 US20220062194A1 (en) 2010-11-08 2021-11-18 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
US17/823,793 US20230110784A1 (en) 2010-11-08 2022-08-31 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41143710P 2010-11-08 2010-11-08
US41143110P 2010-11-08 2010-11-08
US201161482994P 2011-05-05 2011-05-05
US13/290,868 US20120115849A1 (en) 2010-11-08 2011-11-07 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/835,607 Continuation-In-Part US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US15/871,768 Continuation US11207275B2 (en) 2010-11-08 2018-01-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors

Publications (1)

Publication Number Publication Date
US20120115849A1 true US20120115849A1 (en) 2012-05-10

Family

ID=48607500

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/290,868 Abandoned US20120115849A1 (en) 2010-11-08 2011-11-07 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
US15/871,768 Active US11207275B2 (en) 2010-11-08 2018-01-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US17/530,011 Abandoned US20220062194A1 (en) 2010-11-08 2021-11-18 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/871,768 Active US11207275B2 (en) 2010-11-08 2018-01-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US17/530,011 Abandoned US20220062194A1 (en) 2010-11-08 2021-11-18 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors

Country Status (14)

Country Link
US (3) US20120115849A1 (de)
EP (2) EP4275752A3 (de)
JP (8) JP2014504271A (de)
KR (7) KR102054899B1 (de)
CN (3) CN103547267A (de)
AU (1) AU2011326173B2 (de)
BR (1) BR112013011419B1 (de)
CA (1) CA2817071C (de)
CL (1) CL2013001136A1 (de)
IL (1) IL226203B (de)
MX (1) MX2013004943A (de)
NZ (3) NZ610925A (de)
RU (1) RU2661410C2 (de)
WO (1) WO2012064667A2 (de)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2017049158A1 (en) * 2015-09-16 2017-03-23 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
WO2021046183A1 (en) * 2019-09-05 2021-03-11 Trevena, Inc. Methods of treating epilepsy using the same
US10961244B2 (en) 2016-03-25 2021-03-30 The Trustees Of Columbia University In The City Of New York Mitragynine alkaloids as opioid receptor modulators
US20210283126A1 (en) * 2010-12-03 2021-09-16 Nalpropion Pharmaceuticals Llc Methods For Reducing Binge Or Compulsive Eating
US11207275B2 (en) 2010-11-08 2021-12-28 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US11464785B2 (en) 2010-11-08 2022-10-11 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2023064228A1 (en) * 2021-10-11 2023-04-20 Anebulo Pharmaceuticals, Inc. Method of treating addiction
US11795146B2 (en) 2021-10-11 2023-10-24 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof
US11884655B2 (en) 2019-11-19 2024-01-30 Trevena, Inc. Compounds and methods of preparing compounds S1P1 modulators
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance
US11912693B2 (en) 2017-06-14 2024-02-27 Trevena, Inc. Compounds for modulating S1P1 activity and methods of using the same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521177A (ja) * 2012-05-07 2015-07-27 オメロス コーポレーション Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置
TW201613590A (en) * 2014-09-12 2016-04-16 Purdue Pharma Lp Systems and methods for attenuating opioid-induced euphoria
WO2016130043A1 (ru) * 2015-02-13 2016-08-18 Александ Васильевич ИВАЩЕНКО Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
WO2020183350A1 (en) * 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Transdermal patch kit with transdermal dosage units
CN111494383B (zh) * 2020-06-04 2021-03-19 牡丹江医学院 一种预防和治疗酒精引起焦虑的药物组合物

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0306531A4 (de) 1986-12-11 1989-04-12 Toray Industries Flexible wärmetransporteinrichtung und methode zu ihrer herstellung.
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
WO1994021244A1 (en) * 1993-03-17 1994-09-29 Pietr Hitzig Method of treating addictive behaviors
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
CN1045718C (zh) * 1995-11-06 1999-10-20 西安天诚医药生物工程有限公司 青藤碱的医药新用途
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
AU4145200A (en) 1999-05-07 2000-11-21 Takeda Chemical Industries Ltd. Cyclic compounds and uses thereof
US6146876A (en) 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
PL197981B1 (pl) * 1999-07-01 2008-05-30 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
DE19950647A1 (de) 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
US7491742B2 (en) 1999-10-21 2009-02-17 Merck Patent Gmbh Imidazole derivatives as phosphodiesterase VII inhibitors
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953024A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
AU4415501A (en) 2000-02-24 2001-09-03 Bayer Aktiengesellschaft Regulation of human gelatinase b-like enzyme 1
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
GB0015095D0 (en) 2000-06-20 2000-08-09 Celltech Chiroscience Ltd Chemical compounds
JP2004515053A (ja) * 2000-06-26 2004-05-20 アプライド　マテリアルズ　インコーポレイテッド ウェーハ洗浄方法及び装置
EP1193261A1 (de) 2000-10-02 2002-04-03 Warner-Lambert Company Thiadiazole und ihre Verwendung als Phosphodiesterase-7 Inhibitoren
WO2002040449A1 (en) 2000-11-14 2002-05-23 Altana Pharma Ag Dihydroisoquinolines as novel phosphodiesterase inhibitors
AU2954102A (en) 2000-11-14 2002-05-27 Byk Gulden Lomberg Chem Fab (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
US6617357B2 (en) 2001-03-06 2003-09-09 Smithkline Beecham Corporation Compounds and their use as PDE inhibitors
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6958328B2 (en) 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
US6903109B2 (en) 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
WO2002085894A1 (en) 2001-04-18 2002-10-31 Ortho-Mcneil Pharmaceutical, Inc. Arylindenopyridines with pde inhibiting activity
SK14342003A3 (sk) 2001-04-25 2004-05-04 Altana Pharma Ag Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie
CN100343258C (zh) 2001-04-30 2007-10-17 美国拜尔公司 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
US20030053980A1 (en) 2001-04-30 2003-03-20 The Gillette Company Shaving compositions containing highly lubricious water soluble polymers
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
EP1397142A4 (de) 2001-06-19 2004-11-03 Bristol Myers Squibb Co Pyrimidin-hemmer der phosphodiesterase (pde) 7
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
CN1264843C (zh) 2001-12-13 2006-07-19 第一阿斯比奥制药株式会社 具有pde7抑制作用的吡唑并嘧啶酮衍生物
DE10163991A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
AU2002360774A1 (en) 2001-12-28 2003-07-24 Bayer Corporation 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
WO2003064389A1 (fr) 2002-01-31 2003-08-07 Ono Pharmaceutical Co., Ltd. Composes bicycliques contenant de l'azote et medicaments contenant ces composes en tant qu'ingredient actif
EP1348701A1 (de) 2002-03-28 2003-10-01 Warner-Lambert Company LLC 2,4-disubstituierte Thiazol-5-yl-Amine als PDE7-Inhibitoren
EP1348433A1 (de) 2002-03-28 2003-10-01 Warner-Lambert Company LLC Thiazol-5-yl-imine als PDE7-Inhibitoren
EP1400244A1 (de) 2002-09-17 2004-03-24 Warner-Lambert Company LLC Neue spirokondensierte Chinazolinone und ihre Verwendung als Phosphodiesteraseinhibitoren
WO2004044196A1 (en) 2002-11-13 2004-05-27 Bayer Healthcare Ag DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b)
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
AU2004232973A1 (en) * 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2007506440A (ja) 2003-09-29 2007-03-22 トピジェン・ファルマスーティック・インコーポレーテッド 炎症性症状を含む疾患を治療するための、オリゴヌクレオチド組成物および方法
US20080282364A1 (en) * 2003-10-31 2008-11-13 Shawn C Black Phosphodiesterase 9 Inhibition as Treatment for Obesity-Related Conditions
RU2376309C2 (ru) 2004-07-01 2009-12-20 Асубио Фарма Ко., Лтд. Производное тиенопиразола, имеющее ингибирующую фосфодиэстеразу 7 (pde 7) активность
RU2252038C1 (ru) * 2004-07-30 2005-05-20 Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук Способ интерактивного лечения зависимого поведения
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
US20090111837A1 (en) 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
PL1928438T3 (pl) * 2005-09-26 2013-08-30 Avigen Inc Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających
EP2377530A3 (de) * 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EA200801145A1 (ru) 2005-12-02 2008-10-30 Пфайзер Лимитед Спироциклические производные хиназолина в качестве ингибиторов pde7
TW200734933A (en) * 2006-03-06 2007-09-16 Pixart Imaging Inc Dot-matrix pattern design and decoding method and the device thereof
WO2007128884A1 (en) 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
ES2308916B1 (es) 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
CA2681650C (en) * 2007-03-27 2016-11-22 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008130619A2 (en) 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
US20100216823A1 (en) 2007-05-24 2010-08-26 Pfizer Inc. Spirocyclic Derivatives
RU2351371C1 (ru) * 2007-11-12 2009-04-10 Ринат Равильевич Саберов Способ лечения компульсивного обжорства
EP3246034A1 (de) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boronhaltige kleinmoleküle als entzündungshemmende wirkstoffe
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20110230504A1 (en) 2008-09-15 2011-09-22 The Regents Of The University Of California Office Of Technology ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP
JP2012502977A (ja) * 2008-09-19 2012-02-02 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼ阻害薬
FR2943673B1 (fr) 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
JP2015521177A (ja) 2012-05-07 2015-07-27 オメロス コーポレーション Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464785B2 (en) 2010-11-08 2022-10-11 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US11207275B2 (en) 2010-11-08 2021-12-28 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US20210283126A1 (en) * 2010-12-03 2021-09-16 Nalpropion Pharmaceuticals Llc Methods For Reducing Binge Or Compulsive Eating
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US8889190B2 (en) 2013-03-13 2014-11-18 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10363224B2 (en) 2013-03-13 2019-07-30 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9555005B2 (en) 2013-03-15 2017-01-31 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10172878B2 (en) 2013-03-15 2019-01-08 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
WO2017049158A1 (en) * 2015-09-16 2017-03-23 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
AU2016323977B9 (en) * 2015-09-16 2021-03-04 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
AU2016323977B2 (en) * 2015-09-16 2021-02-25 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
US10844027B2 (en) 2015-09-16 2020-11-24 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
US10961244B2 (en) 2016-03-25 2021-03-30 The Trustees Of Columbia University In The City Of New York Mitragynine alkaloids as opioid receptor modulators
US11912707B2 (en) 2016-03-25 2024-02-27 The Trustees Of Columbia University In The City Of New York Mitragynine alkaloids as opioid receptor modulators
US11912693B2 (en) 2017-06-14 2024-02-27 Trevena, Inc. Compounds for modulating S1P1 activity and methods of using the same
WO2021046183A1 (en) * 2019-09-05 2021-03-11 Trevena, Inc. Methods of treating epilepsy using the same
US11884655B2 (en) 2019-11-19 2024-01-30 Trevena, Inc. Compounds and methods of preparing compounds S1P1 modulators
US11795146B2 (en) 2021-10-11 2023-10-24 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof
WO2023064228A1 (en) * 2021-10-11 2023-04-20 Anebulo Pharmaceuticals, Inc. Method of treating addiction
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Also Published As

Publication number Publication date
KR20190138708A (ko) 2019-12-13
NZ610925A (en) 2015-10-30
KR102054899B1 (ko) 2019-12-11
JP2019094352A (ja) 2019-06-20
AU2011326173A1 (en) 2013-04-18
JP2024015430A (ja) 2024-02-01
US20220062194A1 (en) 2022-03-03
KR20180100720A (ko) 2018-09-11
BR112013011419A2 (pt) 2016-08-02
MX2013004943A (es) 2013-09-02
CN103547267A (zh) 2014-01-29
EP2640395A4 (de) 2014-01-22
KR20160105948A (ko) 2016-09-07
WO2012064667A3 (en) 2013-11-14
RU2013126476A (ru) 2014-12-20
NZ628054A (en) 2016-03-31
WO2012064667A2 (en) 2012-05-18
BR112013011419B1 (pt) 2023-01-31
JP2022159477A (ja) 2022-10-17
EP4275752A3 (de) 2024-02-21
EP4275752A2 (de) 2023-11-15
RU2661410C2 (ru) 2018-07-16
JP2015071648A (ja) 2015-04-16
CA2817071A1 (en) 2012-05-18
IL226203B (en) 2019-06-30
KR20170136020A (ko) 2017-12-08
JP2016145255A (ja) 2016-08-12
KR20130124333A (ko) 2013-11-13
CN107375296A (zh) 2017-11-24
IL226203A0 (en) 2013-07-31
JP2018048213A (ja) 2018-03-29
KR20220047894A (ko) 2022-04-19
US20180289632A1 (en) 2018-10-11
KR20230104760A (ko) 2023-07-10
CN106038567A (zh) 2016-10-26
AU2011326173B2 (en) 2015-08-27
US11207275B2 (en) 2021-12-28
EP2640395A2 (de) 2013-09-25
JP2014504271A (ja) 2014-02-20
CA2817071C (en) 2018-04-24
CL2013001136A1 (es) 2014-03-07
NZ628055A (en) 2016-03-31
JP2021014461A (ja) 2021-02-12
KR102385359B1 (ko) 2022-04-11

Similar Documents

Publication Publication Date Title
US20220062194A1 (en) Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
US11464785B2 (en) Treatment of addiction and impulse-control disorders using PDE7 inhibitors
EP2846805B1 (de) Behandlung von sucht und impulskontrollstörungen mittels pde7-inhibitoren
JP2021138766A (ja) Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置
US20230110784A1 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
AU2013201989B2 (en) Treatment of addiction and impulse-control disorders using PDE7 inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: OMEROS CORPORATION, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEMOPULOS, GREGORY A.;GAITANARIS, GEORGE A.;SIGNING DATES FROM 20111216 TO 20111219;REEL/FRAME:027484/0337

AS Assignment

Owner name: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT, TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:OMEROS CORPORATION;REEL/FRAME:040575/0110

Effective date: 20161103

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: OMEROS CORPORATION, WASHINGTON

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CRG SERVICING LLC;REEL/FRAME:047573/0577

Effective date: 20181115